CA2445888A1 - Chiral, broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation and compositions - Google Patents
Chiral, broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation and compositions Download PDFInfo
- Publication number
- CA2445888A1 CA2445888A1 CA002445888A CA2445888A CA2445888A1 CA 2445888 A1 CA2445888 A1 CA 2445888A1 CA 002445888 A CA002445888 A CA 002445888A CA 2445888 A CA2445888 A CA 2445888A CA 2445888 A1 CA2445888 A1 CA 2445888A1
- Authority
- CA
- Canada
- Prior art keywords
- amino
- oxo
- dihydro
- quinoline
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 342
- -1 7-substituted piperidino-quinolone carboxylic acid Chemical class 0.000 title claims abstract description 102
- 238000002360 preparation method Methods 0.000 title abstract description 59
- 230000000844 anti-bacterial effect Effects 0.000 title description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 447
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 222
- 238000000034 method Methods 0.000 claims description 126
- 229910052799 carbon Inorganic materials 0.000 claims description 63
- 125000001424 substituent group Chemical group 0.000 claims description 62
- 125000000217 alkyl group Chemical group 0.000 claims description 49
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 48
- 229940124307 fluoroquinolone Drugs 0.000 claims description 47
- 229910052739 hydrogen Inorganic materials 0.000 claims description 46
- 229910052757 nitrogen Inorganic materials 0.000 claims description 45
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 44
- 239000002253 acid Substances 0.000 claims description 37
- 150000001413 amino acids Chemical class 0.000 claims description 37
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 36
- 239000003960 organic solvent Substances 0.000 claims description 31
- 239000001257 hydrogen Substances 0.000 claims description 30
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 26
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 25
- 239000002585 base Substances 0.000 claims description 24
- OKZIUSOJQLYFSE-UHFFFAOYSA-N difluoroboron Chemical compound F[B]F OKZIUSOJQLYFSE-UHFFFAOYSA-N 0.000 claims description 24
- 208000015181 infectious disease Diseases 0.000 claims description 23
- 239000013522 chelant Substances 0.000 claims description 22
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 19
- 125000000539 amino acid group Chemical group 0.000 claims description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 125000001589 carboacyl group Chemical group 0.000 claims description 16
- 238000010438 heat treatment Methods 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 14
- PMBHAWNZPPNADR-UHFFFAOYSA-N 7-(4-amino-3,3-dimethylpiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(N)C(C)(C)C1 PMBHAWNZPPNADR-UHFFFAOYSA-N 0.000 claims description 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 125000003277 amino group Chemical group 0.000 claims description 11
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 10
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 10
- 125000003282 alkyl amino group Chemical group 0.000 claims description 10
- 150000001412 amines Chemical class 0.000 claims description 10
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 10
- 229910052796 boron Inorganic materials 0.000 claims description 10
- 235000012208 gluconic acid Nutrition 0.000 claims description 10
- 230000000699 topical effect Effects 0.000 claims description 10
- 108010016626 Dipeptides Proteins 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 239000000460 chlorine Substances 0.000 claims description 9
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 230000009885 systemic effect Effects 0.000 claims description 9
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 239000000174 gluconic acid Substances 0.000 claims description 8
- 239000003513 alkali Substances 0.000 claims description 7
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 6
- 125000004434 sulfur atom Chemical group 0.000 claims description 6
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims description 6
- WPBQEWYKGUXFAT-UHFFFAOYSA-N 1-cyclopropyl-7-[3,3-dimethyl-4-(phenylmethoxycarbonylamino)piperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N(CC1(C)C)CCC1NC(=O)OCC1=CC=CC=C1 WPBQEWYKGUXFAT-UHFFFAOYSA-N 0.000 claims description 4
- SOWSVRBSHHQLAB-UHFFFAOYSA-N 5-amino-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(C)=C1N1CCC(N)C(C)(C)C1 SOWSVRBSHHQLAB-UHFFFAOYSA-N 0.000 claims description 4
- DWHXCQMDSVTVCU-UHFFFAOYSA-N 7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,8-diethyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2CC)=O)=C2C(CC)=C1N1CCC(N)C(C)(C)C1 DWHXCQMDSVTVCU-UHFFFAOYSA-N 0.000 claims description 4
- BDSBSELVBOBYOQ-UHFFFAOYSA-N 7-(4-amino-3,3-dimethylpiperidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C=3C(=CC(F)=CC=3)F)=O)=C2C(C)=C1N1CCC(N)C(C)(C)C1 BDSBSELVBOBYOQ-UHFFFAOYSA-N 0.000 claims description 4
- CWIBZDKDJUMICC-UHFFFAOYSA-N 7-(4-amino-3,3-dimethylpiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(C)=C1N1CCC(N)C(C)(C)C1 CWIBZDKDJUMICC-UHFFFAOYSA-N 0.000 claims description 4
- BLSDIPBMJIFTBY-UHFFFAOYSA-N 7-(4-amino-3,3-dimethylpiperidin-1-yl)-1-cyclopropyl-8-ethyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(CC)=C1N1CCC(N)C(C)(C)C1 BLSDIPBMJIFTBY-UHFFFAOYSA-N 0.000 claims description 4
- AALWVRXNONLKQH-UHFFFAOYSA-N 7-(4-amino-3,3-dimethylpiperidin-1-yl)-1-ethyl-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound CC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCC(N)C(C)(C)C1 AALWVRXNONLKQH-UHFFFAOYSA-N 0.000 claims description 4
- FKQVCNIEJCPZQT-MEBBXXQBSA-N 7-[(3r,4r)-4-amino-3-methylpiperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CC[C@@H](N)[C@H](C)C1 FKQVCNIEJCPZQT-MEBBXXQBSA-N 0.000 claims description 4
- 125000004442 acylamino group Chemical group 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 229910000085 borane Inorganic materials 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- AJZGLHJVIGMIIQ-UHFFFAOYSA-N 1-cyclopropyl-7-[4-(ethylamino)-3-methylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(C)C(NCC)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC AJZGLHJVIGMIIQ-UHFFFAOYSA-N 0.000 claims description 3
- GIRLROWRRLTKFZ-UHFFFAOYSA-N 5-amino-1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound COC1=C(F)C(F)=C(N)C(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 GIRLROWRRLTKFZ-UHFFFAOYSA-N 0.000 claims description 3
- ODDBWDOIFIWNOL-UHFFFAOYSA-N 5-amino-1-cyclopropyl-7-[4-(dimethylamino)-3-methylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(N(C)C)C(C)C1 ODDBWDOIFIWNOL-UHFFFAOYSA-N 0.000 claims description 3
- MZJYKRXJUVVRLL-UHFFFAOYSA-N 7-(4-amino-3,3-dimethylpiperidin-1-yl)-1-(2,4-difluorophenyl)-8-ethyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C=3C(=CC(F)=CC=3)F)=O)=C2C(CC)=C1N1CCC(N)C(C)(C)C1 MZJYKRXJUVVRLL-UHFFFAOYSA-N 0.000 claims description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 3
- 125000003147 glycosyl group Chemical group 0.000 claims description 3
- 150000003459 sulfonic acid esters Chemical class 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000004385 trihaloalkyl group Chemical group 0.000 claims description 3
- UTSTUTABZSMOOJ-UHFFFAOYSA-N 1,8-diethyl-6-fluoro-7-(4-hydroxypiperidin-1-yl)-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2CC)=O)=C2C(CC)=C1N1CCC(O)CC1 UTSTUTABZSMOOJ-UHFFFAOYSA-N 0.000 claims description 2
- BIRRFYKJOVTPGR-BDJLRTHQSA-N 1,8-diethyl-6-fluoro-7-[(3r,4r)-4-hydroxy-3-methylpiperidin-1-yl]-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2CC)=O)=C2C(CC)=C1N1CC[C@@H](O)[C@H](C)C1 BIRRFYKJOVTPGR-BDJLRTHQSA-N 0.000 claims description 2
- YIIYDJHBXHVWFJ-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-6-fluoro-7-(4-hydroxypiperidin-1-yl)-8-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C=3C(=CC(F)=CC=3)F)=O)=C2C(C)=C1N1CCC(O)CC1 YIIYDJHBXHVWFJ-UHFFFAOYSA-N 0.000 claims description 2
- BRCVXCLSBOTCIT-NSPYISDASA-N 1-(2,4-difluorophenyl)-6-fluoro-7-[(3r,4r)-4-hydroxy-3-methylpiperidin-1-yl]-8-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound C1C[C@@H](O)[C@H](C)CN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C=3C(=CC(F)=CC=3)F)C2=C1C BRCVXCLSBOTCIT-NSPYISDASA-N 0.000 claims description 2
- GZPKHJXGWSSWHK-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-8-ethyl-6-fluoro-7-(4-hydroxypiperidin-1-yl)-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C=3C(=CC(F)=CC=3)F)=O)=C2C(CC)=C1N1CCC(O)CC1 GZPKHJXGWSSWHK-UHFFFAOYSA-N 0.000 claims description 2
- SKJVBTKTRDJINY-MPBGBICISA-N 1-(2,4-difluorophenyl)-8-ethyl-6-fluoro-7-[(3r,4r)-4-hydroxy-3-methylpiperidin-1-yl]-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C=3C(=CC(F)=CC=3)F)=O)=C2C(CC)=C1N1CC[C@@H](O)[C@H](C)C1 SKJVBTKTRDJINY-MPBGBICISA-N 0.000 claims description 2
- JSRPSEAHSAOKLP-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-7-(4-hydroxy-3,3-dimethylpiperidin-1-yl)-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(O)C(C)(C)C1 JSRPSEAHSAOKLP-UHFFFAOYSA-N 0.000 claims description 2
- VSNFNFPDOBFPMQ-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-7-(4-hydroxy-3-methylpiperidin-1-yl)-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(O)C(C)C1 VSNFNFPDOBFPMQ-UHFFFAOYSA-N 0.000 claims description 2
- MFIPRAIYMPDRQN-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-7-(4-hydroxy-3-propylpiperidin-1-yl)-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1CC(O)C(CCC)CN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC MFIPRAIYMPDRQN-UHFFFAOYSA-N 0.000 claims description 2
- ADYMQUULBOHOKB-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-7-(4-hydroxy-4-methylpiperidin-1-yl)-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(C)(O)CC1 ADYMQUULBOHOKB-UHFFFAOYSA-N 0.000 claims description 2
- ZQDOMDSNFDESCG-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-7-(4-hydroxypiperidin-1-yl)-8-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(C)=C1N1CCC(O)CC1 ZQDOMDSNFDESCG-UHFFFAOYSA-N 0.000 claims description 2
- QWAKGTVASVYGSD-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-7-[4-hydroxy-4-(trifluoromethyl)piperidin-1-yl]-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(O)(C(F)(F)F)CC1 QWAKGTVASVYGSD-UHFFFAOYSA-N 0.000 claims description 2
- YPVAUCAFVGWRRD-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-8-methoxy-7-[3-methyl-4-(methylamino)piperidin-1-yl]-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(C)C(NC)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC YPVAUCAFVGWRRD-UHFFFAOYSA-N 0.000 claims description 2
- RCELUFUGKXQHNV-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-8-methyl-7-[3-methyl-4-(methylamino)piperidin-1-yl]-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(C)C(NC)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1C RCELUFUGKXQHNV-UHFFFAOYSA-N 0.000 claims description 2
- WCTJNDAOIPAZTB-UHFFFAOYSA-N 1-cyclopropyl-7-[3,3-dimethyl-4-(methylamino)piperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(C)(C)C(NC)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC WCTJNDAOIPAZTB-UHFFFAOYSA-N 0.000 claims description 2
- OCYUILSKZFPISR-UHFFFAOYSA-N 1-cyclopropyl-7-[3-ethyl-3-methyl-4-(methylamino)piperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1CC(NC)C(CC)(C)CN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC OCYUILSKZFPISR-UHFFFAOYSA-N 0.000 claims description 2
- WBQLIOXEADQPNG-UHFFFAOYSA-N 1-cyclopropyl-7-[3-ethyl-4-(methylamino)piperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1CC(NC)C(CC)CN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC WBQLIOXEADQPNG-UHFFFAOYSA-N 0.000 claims description 2
- NSXQTKCKRAQXJU-UHFFFAOYSA-N 1-cyclopropyl-7-[4-(cyclopropylamino)-3,3-dimethylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N(CC1(C)C)CCC1NC1CC1 NSXQTKCKRAQXJU-UHFFFAOYSA-N 0.000 claims description 2
- LMRFKZLZAKKLQL-UHFFFAOYSA-N 1-cyclopropyl-7-[4-(cyclopropylamino)-3,5-dimethylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N(CC1C)CC(C)C1NC1CC1 LMRFKZLZAKKLQL-UHFFFAOYSA-N 0.000 claims description 2
- XTVIEIGAJOQTCY-UHFFFAOYSA-N 1-cyclopropyl-7-[4-(cyclopropylamino)-3-ethylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound CCC1CN(C=2C(=C3C(C(C(C(O)=O)=CN3C3CC3)=O)=CC=2F)OC)CCC1NC1CC1 XTVIEIGAJOQTCY-UHFFFAOYSA-N 0.000 claims description 2
- SIKQBMFDHCUFCC-UHFFFAOYSA-N 1-cyclopropyl-7-[4-(dimethylamino)-3,3-dimethylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(N(C)C)C(C)(C)C1 SIKQBMFDHCUFCC-UHFFFAOYSA-N 0.000 claims description 2
- QHSJROCJBXRWGO-UHFFFAOYSA-N 1-cyclopropyl-7-[4-(dimethylamino)-3,3-dimethylpiperidin-1-yl]-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(C)(C)C(N(C)C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1C QHSJROCJBXRWGO-UHFFFAOYSA-N 0.000 claims description 2
- STTFGQHLZZKTOC-UHFFFAOYSA-N 1-cyclopropyl-7-[4-(dimethylamino)-3,5-dimethylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CC(C)C(N(C)C)C(C)C1 STTFGQHLZZKTOC-UHFFFAOYSA-N 0.000 claims description 2
- XKKKMNYHNZJZNI-UHFFFAOYSA-N 1-cyclopropyl-7-[4-(dimethylamino)-3-ethylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1CC(N(C)C)C(CC)CN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC XKKKMNYHNZJZNI-UHFFFAOYSA-N 0.000 claims description 2
- MZSAPVYMQQRDSY-UHFFFAOYSA-N 1-cyclopropyl-7-[4-(dimethylamino)-3-methylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(N(C)C)C(C)C1 MZSAPVYMQQRDSY-UHFFFAOYSA-N 0.000 claims description 2
- SAMHFFGNBBJKBM-UHFFFAOYSA-N 1-cyclopropyl-7-[4-(dimethylamino)-3-methylpiperidin-1-yl]-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound C1CC(N(C)C)C(C)CN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1C SAMHFFGNBBJKBM-UHFFFAOYSA-N 0.000 claims description 2
- ZREHPVQMLCZWPW-UHFFFAOYSA-N 1-cyclopropyl-7-[4-(ethoxycarbonylamino)-3,3-dimethylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(C)(C)C(NC(=O)OCC)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC ZREHPVQMLCZWPW-UHFFFAOYSA-N 0.000 claims description 2
- KYWNBWYZJSFADV-UHFFFAOYSA-N 1-cyclopropyl-7-[4-(ethylamino)-3,3-dimethylpiperidin-1-yl]-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(C)(C)C(NCC)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1C KYWNBWYZJSFADV-UHFFFAOYSA-N 0.000 claims description 2
- WOAZHUCRASEKJX-UHFFFAOYSA-N 1-cyclopropyl-8-ethyl-6-fluoro-7-(4-hydroxypiperidin-1-yl)-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(CC)=C1N1CCC(O)CC1 WOAZHUCRASEKJX-UHFFFAOYSA-N 0.000 claims description 2
- CKIYQWIJAIZFGL-PIGZYNQJSA-N 1-cyclopropyl-8-ethyl-6-fluoro-7-[(3r,4r)-4-hydroxy-3-methylpiperidin-1-yl]-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(CC)=C1N1CC[C@@H](O)[C@H](C)C1 CKIYQWIJAIZFGL-PIGZYNQJSA-N 0.000 claims description 2
- TZANYWSIWBFKFJ-UHFFFAOYSA-N 1-ethyl-6-fluoro-7-(4-hydroxypiperidin-1-yl)-8-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound CC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCC(O)CC1 TZANYWSIWBFKFJ-UHFFFAOYSA-N 0.000 claims description 2
- SVZYXCYFQWYNKL-MEBBXXQBSA-N 1-ethyl-6-fluoro-7-[(3r,4r)-4-hydroxy-3-methylpiperidin-1-yl]-8-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound CC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CC[C@@H](O)[C@H](C)C1 SVZYXCYFQWYNKL-MEBBXXQBSA-N 0.000 claims description 2
- HVSJKEYNLCXXTF-UHFFFAOYSA-N 5-amino-1-cyclopropyl-6-fluoro-7-(4-hydroxy-3,3,5-trimethylpiperidin-1-yl)-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CC(C)C(O)C(C)(C)C1 HVSJKEYNLCXXTF-UHFFFAOYSA-N 0.000 claims description 2
- JFDWWRTYPKLVGJ-UHFFFAOYSA-N 5-amino-1-cyclopropyl-6-fluoro-7-(4-hydroxy-3,3-dimethylpiperidin-1-yl)-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(O)C(C)(C)C1 JFDWWRTYPKLVGJ-UHFFFAOYSA-N 0.000 claims description 2
- ZMRROSTXVXYRPL-UHFFFAOYSA-N 5-amino-1-cyclopropyl-6-fluoro-7-(4-hydroxy-3,5-dimethylpiperidin-1-yl)-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CC(C)C(O)C(C)C1 ZMRROSTXVXYRPL-UHFFFAOYSA-N 0.000 claims description 2
- PHBSZJLZRXSXLG-UHFFFAOYSA-N 5-amino-1-cyclopropyl-6-fluoro-7-(4-hydroxy-3-methylpiperidin-1-yl)-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(O)C(C)C1 PHBSZJLZRXSXLG-UHFFFAOYSA-N 0.000 claims description 2
- VFXOQRYKHNKFFN-UHFFFAOYSA-N 5-amino-1-cyclopropyl-6-fluoro-7-(4-hydroxy-4-methylpiperidin-1-yl)-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(C)(O)CC1 VFXOQRYKHNKFFN-UHFFFAOYSA-N 0.000 claims description 2
- FBFQGEJRJSQFPO-UHFFFAOYSA-N 5-amino-1-cyclopropyl-6-fluoro-8-methoxy-7-[3-methyl-4-(methylamino)piperidin-1-yl]-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(C)C(NC)CCN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC FBFQGEJRJSQFPO-UHFFFAOYSA-N 0.000 claims description 2
- ZXPDWMIBUOBMIJ-UHFFFAOYSA-N 5-amino-1-cyclopropyl-7-(3-ethyl-4-hydroxypiperidin-1-yl)-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1CC(O)C(CC)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC ZXPDWMIBUOBMIJ-UHFFFAOYSA-N 0.000 claims description 2
- WJKNJWLGDNUXHC-UHFFFAOYSA-N 5-amino-1-cyclopropyl-7-[3,3-dimethyl-4-(methylamino)piperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(C)(C)C(NC)CCN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC WJKNJWLGDNUXHC-UHFFFAOYSA-N 0.000 claims description 2
- YKCRIOPDLAWJDP-UHFFFAOYSA-N 5-amino-1-cyclopropyl-7-[3,3-dimethyl-4-(phenylmethoxycarbonylamino)piperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N(CC1(C)C)CCC1NC(=O)OCC1=CC=CC=C1 YKCRIOPDLAWJDP-UHFFFAOYSA-N 0.000 claims description 2
- JPSCJCKPZARMPG-UHFFFAOYSA-N 5-amino-1-cyclopropyl-7-[3,3-dimethyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]piperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(NC(=O)OC(C)(C)C)C(C)(C)C1 JPSCJCKPZARMPG-UHFFFAOYSA-N 0.000 claims description 2
- QYXRIBIYBTWRBF-UHFFFAOYSA-N 5-amino-1-cyclopropyl-7-[3,5-dimethyl-4-(methylamino)piperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(C)C(NC)C(C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC QYXRIBIYBTWRBF-UHFFFAOYSA-N 0.000 claims description 2
- RPKSLXMVKIDARG-UHFFFAOYSA-N 5-amino-1-cyclopropyl-7-[4-(cyclopropylamino)-3,5-dimethylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N(CC1C)CC(C)C1NC1CC1 RPKSLXMVKIDARG-UHFFFAOYSA-N 0.000 claims description 2
- UOTSEQLVDXZOJK-UHFFFAOYSA-N 5-amino-1-cyclopropyl-7-[4-(cyclopropylamino)-3-ethylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound CCC1CN(C=2C(=C3C(C(C(C(O)=O)=CN3C3CC3)=O)=C(N)C=2F)OC)CCC1NC1CC1 UOTSEQLVDXZOJK-UHFFFAOYSA-N 0.000 claims description 2
- QCOVJFDRMPJLMR-UHFFFAOYSA-N 5-amino-1-cyclopropyl-7-[4-(dimethylamino)-3,3-dimethylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(N(C)C)C(C)(C)C1 QCOVJFDRMPJLMR-UHFFFAOYSA-N 0.000 claims description 2
- MRUMNJDXMQRIPA-UHFFFAOYSA-N 5-amino-1-cyclopropyl-7-[4-(dimethylamino)-3,5-dimethylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CC(C)C(N(C)C)C(C)C1 MRUMNJDXMQRIPA-UHFFFAOYSA-N 0.000 claims description 2
- SBKCWRWBCQUJIR-UHFFFAOYSA-N 5-amino-1-cyclopropyl-7-[4-(dimethylamino)-3-ethyl-3-methylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1CC(N(C)C)C(CC)(C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC SBKCWRWBCQUJIR-UHFFFAOYSA-N 0.000 claims description 2
- UYIKQMYLBXGDOQ-UHFFFAOYSA-N 5-amino-1-cyclopropyl-7-[4-(ethoxycarbonylamino)-3,3-dimethylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(C)(C)C(NC(=O)OCC)CCN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC UYIKQMYLBXGDOQ-UHFFFAOYSA-N 0.000 claims description 2
- WQSQBIWKXFBZDI-UHFFFAOYSA-N 5-amino-1-cyclopropyl-7-[4-(ethylamino)-3,3-dimethylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(C)(C)C(NCC)CCN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC WQSQBIWKXFBZDI-UHFFFAOYSA-N 0.000 claims description 2
- VHMOQXXAZJHHNR-UHFFFAOYSA-N 5-amino-1-cyclopropyl-7-[4-(ethylamino)-3,5-dimethylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(C)C(NCC)C(C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC VHMOQXXAZJHHNR-UHFFFAOYSA-N 0.000 claims description 2
- PFDYGIFPWFBRNX-UHFFFAOYSA-N 5-amino-1-cyclopropyl-7-[4-(ethylamino)-3-methylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(C)C(NCC)CCN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC PFDYGIFPWFBRNX-UHFFFAOYSA-N 0.000 claims description 2
- FLKXLIKUHDDZJV-UHFFFAOYSA-N 5-amino-7-(4-amino-3,3,5-trimethylpiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CC(C)C(N)C(C)(C)C1 FLKXLIKUHDDZJV-UHFFFAOYSA-N 0.000 claims description 2
- XRPBISLGNJJGBN-UHFFFAOYSA-N 5-amino-7-(4-amino-3,3-diethylpiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1CC(N)C(CC)(CC)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC XRPBISLGNJJGBN-UHFFFAOYSA-N 0.000 claims description 2
- NDABYINHXHKLMY-UHFFFAOYSA-N 5-amino-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(N)C(C)(C)C1 NDABYINHXHKLMY-UHFFFAOYSA-N 0.000 claims description 2
- DFXZQPJLTMOAKH-UHFFFAOYSA-N 5-amino-7-(4-amino-3,5-diethyl-3-methylpiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(C)(CC)C(N)C(CC)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC DFXZQPJLTMOAKH-UHFFFAOYSA-N 0.000 claims description 2
- ILCINNUUWYAYNL-UHFFFAOYSA-N 5-amino-7-(4-amino-3,5-dimethylpiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CC(C)C(N)C(C)C1 ILCINNUUWYAYNL-UHFFFAOYSA-N 0.000 claims description 2
- IOKXBLACFYVZQG-UHFFFAOYSA-N 5-amino-7-(4-amino-3-ethylpiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1CC(N)C(CC)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC IOKXBLACFYVZQG-UHFFFAOYSA-N 0.000 claims description 2
- VWQAQWDYTJFQAE-UHFFFAOYSA-N 5-amino-7-(4-amino-3-methylpiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(N)C(C)C1 VWQAQWDYTJFQAE-UHFFFAOYSA-N 0.000 claims description 2
- GMCFMZGURBNIJL-UHFFFAOYSA-N 5-amino-7-[3-(aminomethyl)-4-hydroxypiperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(O)C(CN)C1 GMCFMZGURBNIJL-UHFFFAOYSA-N 0.000 claims description 2
- APSVOZCIUFSULV-UHFFFAOYSA-N 7-(4-acetamido-3,3-dimethylpiperidin-1-yl)-5-amino-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(NC(C)=O)C(C)(C)C1 APSVOZCIUFSULV-UHFFFAOYSA-N 0.000 claims description 2
- QKWXABBYMIFOIY-UHFFFAOYSA-N 7-(4-amino-3,3-diethylpiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1CC(N)C(CC)(CC)CN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC QKWXABBYMIFOIY-UHFFFAOYSA-N 0.000 claims description 2
- YYBWFHDLGLBCDF-UHFFFAOYSA-N 7-(4-amino-3,3-dimethylpiperidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C=3C(=CC(F)=CC=3)F)=O)=C2C(OC)=C1N1CCC(N)C(C)(C)C1 YYBWFHDLGLBCDF-UHFFFAOYSA-N 0.000 claims description 2
- TVUFPIGMWGCYET-UHFFFAOYSA-N 7-(4-amino-3,3-dimethylpiperidin-1-yl)-1-ethyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound COC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCC(N)C(C)(C)C1 TVUFPIGMWGCYET-UHFFFAOYSA-N 0.000 claims description 2
- WFVBVDCOWIUOBX-UHFFFAOYSA-N 7-(4-amino-3,5-dimethylpiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CC(C)C(N)C(C)C1 WFVBVDCOWIUOBX-UHFFFAOYSA-N 0.000 claims description 2
- XYIORUDEFOHUCU-UHFFFAOYSA-N 7-(4-amino-3-ethyl-3,5-dimethylpiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(C)C(N)C(CC)(C)CN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC XYIORUDEFOHUCU-UHFFFAOYSA-N 0.000 claims description 2
- XKGJZCWVWCHZDO-UHFFFAOYSA-N 7-(4-amino-3-ethyl-3-methylpiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1CC(N)C(CC)(C)CN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC XKGJZCWVWCHZDO-UHFFFAOYSA-N 0.000 claims description 2
- LTVWOFGNJAMSKX-UHFFFAOYSA-N 7-(4-amino-3-ethylpiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1CC(N)C(CC)CN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC LTVWOFGNJAMSKX-UHFFFAOYSA-N 0.000 claims description 2
- FKQVCNIEJCPZQT-UHFFFAOYSA-N 7-(4-amino-3-methylpiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(N)C(C)C1 FKQVCNIEJCPZQT-UHFFFAOYSA-N 0.000 claims description 2
- UVUSISHPLOKNKM-UHFFFAOYSA-N 7-(4-aminopiperidin-1-yl)-1,8-diethyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2CC)=O)=C2C(CC)=C1N1CCC(N)CC1 UVUSISHPLOKNKM-UHFFFAOYSA-N 0.000 claims description 2
- YNCHHNAQWUYDIM-UHFFFAOYSA-N 7-(4-aminopiperidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C=3C(=CC(F)=CC=3)F)=O)=C2C(C)=C1N1CCC(N)CC1 YNCHHNAQWUYDIM-UHFFFAOYSA-N 0.000 claims description 2
- BOBMTVNBGXDLRZ-UHFFFAOYSA-N 7-(4-aminopiperidin-1-yl)-1-(2,4-difluorophenyl)-8-ethyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C=3C(=CC(F)=CC=3)F)=O)=C2C(CC)=C1N1CCC(N)CC1 BOBMTVNBGXDLRZ-UHFFFAOYSA-N 0.000 claims description 2
- ITVAPWOAEHVRON-UHFFFAOYSA-N 7-(4-aminopiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(C)=C1N1CCC(N)CC1 ITVAPWOAEHVRON-UHFFFAOYSA-N 0.000 claims description 2
- ULXGWVFYSUWFIR-UHFFFAOYSA-N 7-(4-aminopiperidin-1-yl)-1-cyclopropyl-8-ethyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(CC)=C1N1CCC(N)CC1 ULXGWVFYSUWFIR-UHFFFAOYSA-N 0.000 claims description 2
- IRQJEPNRBSICMH-UHFFFAOYSA-N 7-(4-aminopiperidin-1-yl)-1-ethyl-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound CC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCC(N)CC1 IRQJEPNRBSICMH-UHFFFAOYSA-N 0.000 claims description 2
- QNNHERLTFGYZFS-BDJLRTHQSA-N 7-[(3r,4r)-4-amino-3-methylpiperidin-1-yl]-1,8-diethyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2CC)=O)=C2C(CC)=C1N1CC[C@@H](N)[C@H](C)C1 QNNHERLTFGYZFS-BDJLRTHQSA-N 0.000 claims description 2
- BCVAMDPUKLPDNZ-ADLMAVQZSA-N 7-[(3r,4r)-4-amino-3-methylpiperidin-1-yl]-1-(2,4-difluorophenyl)-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound C1C[C@@H](N)[C@H](C)CN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C=3C(=CC(F)=CC=3)F)C2=C1C BCVAMDPUKLPDNZ-ADLMAVQZSA-N 0.000 claims description 2
- QHCUWXGKRRWDPY-CWTRNNRKSA-N 7-[(3r,4r)-4-amino-3-methylpiperidin-1-yl]-1-(2,4-difluorophenyl)-8-ethyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C=3C(=CC(F)=CC=3)F)=O)=C2C(CC)=C1N1CC[C@@H](N)[C@H](C)C1 QHCUWXGKRRWDPY-CWTRNNRKSA-N 0.000 claims description 2
- MSCCGPJQCRJSCB-PIGZYNQJSA-N 7-[(3r,4r)-4-amino-3-methylpiperidin-1-yl]-1-cyclopropyl-8-ethyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(CC)=C1N1CC[C@@H](N)[C@H](C)C1 MSCCGPJQCRJSCB-PIGZYNQJSA-N 0.000 claims description 2
- VUGJBJHJEWISRO-UHFFFAOYSA-N 7-[3,5-dimethyl-4-(methylamino)piperidin-1-yl]-1-ethyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound COC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CC(C)C(NC)C(C)C1 VUGJBJHJEWISRO-UHFFFAOYSA-N 0.000 claims description 2
- ISPVACVJFUIDPD-UHFFFAOYSA-N 7-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound C12=CC(Cl)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 ISPVACVJFUIDPD-UHFFFAOYSA-N 0.000 claims description 2
- 101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims 4
- VWQAQWDYTJFQAE-BXKDBHETSA-N 5-amino-7-[(3r,4r)-4-amino-3-methylpiperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CC[C@@H](N)[C@H](C)C1 VWQAQWDYTJFQAE-BXKDBHETSA-N 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 125000002351 beta-D-glucopyranosyloxy group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 2
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- YCKFHFFSDLPAKF-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-7-(4-hydroxy-3,3,5-trimethylpiperidin-1-yl)-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CC(C)C(O)C(C)(C)C1 YCKFHFFSDLPAKF-UHFFFAOYSA-N 0.000 claims 1
- LNSAAGBMJLLLKJ-UHFFFAOYSA-N 1-cyclopropyl-7-(3-ethyl-4-hydroxypiperidin-1-yl)-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1CC(O)C(CC)CN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC LNSAAGBMJLLLKJ-UHFFFAOYSA-N 0.000 claims 1
- AWTOOJJUZFELOB-UHFFFAOYSA-N 1-cyclopropyl-7-[3,3-dimethyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]piperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(NC(=O)OC(C)(C)C)C(C)(C)C1 AWTOOJJUZFELOB-UHFFFAOYSA-N 0.000 claims 1
- GGHNGUZZIFQUHK-UHFFFAOYSA-N 1-cyclopropyl-7-[3,5-dimethyl-4-(methylamino)piperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(C)C(NC)C(C)CN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC GGHNGUZZIFQUHK-UHFFFAOYSA-N 0.000 claims 1
- HHDYGPSHJKXNON-UHFFFAOYSA-N 1-cyclopropyl-7-[4-(cyclopropylamino)-3-ethyl-3-methylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound CCC1(C)CN(C=2C(=C3C(C(C(C(O)=O)=CN3C3CC3)=O)=CC=2F)OC)CCC1NC1CC1 HHDYGPSHJKXNON-UHFFFAOYSA-N 0.000 claims 1
- QNKUVSSRZPXKCZ-UHFFFAOYSA-N 1-cyclopropyl-7-[4-(cyclopropylamino)-3-methylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N(CC1C)CCC1NC1CC1 QNKUVSSRZPXKCZ-UHFFFAOYSA-N 0.000 claims 1
- QMJALDCTLKTBCC-UHFFFAOYSA-N 1-cyclopropyl-7-[4-(ethylamino)-3,3-dimethylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(C)(C)C(NCC)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC QMJALDCTLKTBCC-UHFFFAOYSA-N 0.000 claims 1
- VXJKPXJWIQCESI-UHFFFAOYSA-N 1-cyclopropyl-7-[4-(ethylamino)-3,5-dimethylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(C)C(NCC)C(C)CN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC VXJKPXJWIQCESI-UHFFFAOYSA-N 0.000 claims 1
- UFGWFRVZQPYPOU-UHFFFAOYSA-N 5-amino-1-cyclopropyl-6-fluoro-7-(4-hydroxy-3-propan-2-ylpiperidin-1-yl)-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(O)C(C(C)C)C1 UFGWFRVZQPYPOU-UHFFFAOYSA-N 0.000 claims 1
- CEOQGAZGQTVEMY-UHFFFAOYSA-N 5-amino-1-cyclopropyl-6-fluoro-7-[4-hydroxy-3-(2-methylpropyl)piperidin-1-yl]-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(O)C(CC(C)C)C1 CEOQGAZGQTVEMY-UHFFFAOYSA-N 0.000 claims 1
- OGTLGDKKIIUROF-UHFFFAOYSA-N 5-amino-1-cyclopropyl-6-fluoro-7-[4-hydroxy-4-(trifluoromethyl)piperidin-1-yl]-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(O)(C(F)(F)F)CC1 OGTLGDKKIIUROF-UHFFFAOYSA-N 0.000 claims 1
- QOGDNWKBODDBDD-UHFFFAOYSA-N 5-amino-1-cyclopropyl-7-[3-ethyl-4-(methylamino)piperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1CC(NC)C(CC)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC QOGDNWKBODDBDD-UHFFFAOYSA-N 0.000 claims 1
- IUWCSTKMJHZIDG-UHFFFAOYSA-N 5-amino-1-cyclopropyl-7-[4-(cyclopropylamino)-3,3-dimethylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N(CC1(C)C)CCC1NC1CC1 IUWCSTKMJHZIDG-UHFFFAOYSA-N 0.000 claims 1
- MJXXTQYRNULOLG-UHFFFAOYSA-N 5-amino-1-cyclopropyl-7-[4-(cyclopropylamino)-3-ethyl-3-methylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound CCC1(C)CN(C=2C(=C3C(C(C(C(O)=O)=CN3C3CC3)=O)=C(N)C=2F)OC)CCC1NC1CC1 MJXXTQYRNULOLG-UHFFFAOYSA-N 0.000 claims 1
- AHAXEXCTXQYURG-UHFFFAOYSA-N 5-amino-1-cyclopropyl-7-[4-(cyclopropylamino)-3-methylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=C(N)C(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N(CC1C)CCC1NC1CC1 AHAXEXCTXQYURG-UHFFFAOYSA-N 0.000 claims 1
- VXBKBWWLOXKLIM-UHFFFAOYSA-N 5-amino-1-cyclopropyl-7-[4-(dimethylamino)-3-ethylpiperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1CC(N(C)C)C(CC)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC VXBKBWWLOXKLIM-UHFFFAOYSA-N 0.000 claims 1
- YWJGJOBJFJOLAG-UHFFFAOYSA-N 5-amino-7-(4-amino-3-ethyl-3,5-dimethylpiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(C)C(N)C(CC)(C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC YWJGJOBJFJOLAG-UHFFFAOYSA-N 0.000 claims 1
- CRHWGUGMZHKRHJ-UHFFFAOYSA-N 5-amino-7-(4-amino-3-ethyl-3-methylpiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1CC(N)C(CC)(C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC CRHWGUGMZHKRHJ-UHFFFAOYSA-N 0.000 claims 1
- KLFCACXBBQWYBO-NOZJJQNGSA-N 5-amino-7-[(3r,4r)-4-amino-3-methylpiperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound C1C[C@@H](N)[C@H](C)CN1C(C(=C1N)F)=C(C)C2=C1C(=O)C(C(O)=O)=CN2C1CC1 KLFCACXBBQWYBO-NOZJJQNGSA-N 0.000 claims 1
- JRPFSSHECNAZLY-UHFFFAOYSA-N 7-(4-acetamido-3,3-dimethylpiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(NC(C)=O)C(C)(C)C1 JRPFSSHECNAZLY-UHFFFAOYSA-N 0.000 claims 1
- OZKSJDYCLMSOBX-UHFFFAOYSA-N 7-(4-amino-3,3,5-trimethylpiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CC(C)C(N)C(C)(C)C1 OZKSJDYCLMSOBX-UHFFFAOYSA-N 0.000 claims 1
- VUTIWJXHCLPUAF-UHFFFAOYSA-N 7-(4-amino-3,5-diethyl-3-methylpiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1C(C)(CC)C(N)C(CC)CN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC VUTIWJXHCLPUAF-UHFFFAOYSA-N 0.000 claims 1
- SIGRZPQSQVNFPZ-QLJPJBMISA-N 7-[(3r,4r)-4-amino-3-methylpiperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound C1C[C@@H](N)[C@H](C)CN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1C SIGRZPQSQVNFPZ-QLJPJBMISA-N 0.000 claims 1
- NDOZWLIOAXKRQZ-MEBBXXQBSA-N 7-[(3r,4r)-4-amino-3-methylpiperidin-1-yl]-1-ethyl-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylic acid Chemical compound CC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CC[C@@H](N)[C@H](C)C1 NDOZWLIOAXKRQZ-MEBBXXQBSA-N 0.000 claims 1
- WWKXHDITLKOVKN-UHFFFAOYSA-N 7-[3-(aminomethylidene)-4-hydroxypiperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(O)C(=CN)C1 WWKXHDITLKOVKN-UHFFFAOYSA-N 0.000 claims 1
- 229910018828 PO3H2 Inorganic materials 0.000 claims 1
- 229910006069 SO3H Inorganic materials 0.000 claims 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 abstract description 27
- 230000003287 optical effect Effects 0.000 abstract description 26
- 230000000845 anti-microbial effect Effects 0.000 abstract description 12
- 238000001228 spectrum Methods 0.000 abstract description 4
- 239000000651 prodrug Substances 0.000 abstract description 3
- 229940002612 prodrug Drugs 0.000 abstract description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 484
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 288
- 235000002639 sodium chloride Nutrition 0.000 description 265
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 208
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 204
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 129
- 239000000243 solution Substances 0.000 description 122
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 121
- 239000011541 reaction mixture Substances 0.000 description 80
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 73
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 70
- 125000006519 CCH3 Chemical group 0.000 description 67
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 65
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 58
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 54
- 239000007787 solid Substances 0.000 description 54
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 51
- 238000003756 stirring Methods 0.000 description 43
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
- 239000000047 product Substances 0.000 description 40
- 101150041968 CDC13 gene Proteins 0.000 description 37
- 230000000694 effects Effects 0.000 description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 35
- BCSXUVZTKVXBSD-UHFFFAOYSA-N 3-methylpiperidin-4-amine Chemical class CC1CNCCC1N BCSXUVZTKVXBSD-UHFFFAOYSA-N 0.000 description 33
- 239000010410 layer Substances 0.000 description 33
- 239000003921 oil Substances 0.000 description 33
- 235000019198 oils Nutrition 0.000 description 32
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 31
- 150000007660 quinolones Chemical class 0.000 description 31
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 30
- 239000000725 suspension Substances 0.000 description 30
- 150000002148 esters Chemical class 0.000 description 28
- 235000019441 ethanol Nutrition 0.000 description 28
- 229940024606 amino acid Drugs 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 26
- FHWXHXRRCMIUIK-UHFFFAOYSA-N n,3,3-trimethylpiperidin-4-amine Chemical compound CNC1CCNCC1(C)C FHWXHXRRCMIUIK-UHFFFAOYSA-N 0.000 description 26
- 150000001721 carbon Chemical group 0.000 description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 24
- 238000007792 addition Methods 0.000 description 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 23
- 239000003814 drug Substances 0.000 description 23
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 239000003054 catalyst Substances 0.000 description 21
- 239000000706 filtrate Substances 0.000 description 21
- 239000012535 impurity Substances 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 239000002024 ethyl acetate extract Substances 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 18
- 238000001816 cooling Methods 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 239000012298 atmosphere Substances 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 229960003702 moxifloxacin Drugs 0.000 description 16
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 16
- 229910052763 palladium Inorganic materials 0.000 description 16
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 15
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 15
- 239000000284 extract Substances 0.000 description 14
- 244000052769 pathogen Species 0.000 description 14
- XJSUUJDMFDMIGK-UHFFFAOYSA-N 3,5-dimethylpiperidin-4-amine Chemical compound CC1CNCC(C)C1N XJSUUJDMFDMIGK-UHFFFAOYSA-N 0.000 description 13
- 238000001704 evaporation Methods 0.000 description 13
- 238000002953 preparative HPLC Methods 0.000 description 13
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 12
- 239000005695 Ammonium acetate Substances 0.000 description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 229940043376 ammonium acetate Drugs 0.000 description 12
- 235000019257 ammonium acetate Nutrition 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- SHTUTXIOXCCHBW-UHFFFAOYSA-N ethyl 4-amino-3,5-dimethylpiperidine-1-carboxylate Chemical compound CCOC(=O)N1CC(C)C(N)C(C)C1 SHTUTXIOXCCHBW-UHFFFAOYSA-N 0.000 description 11
- 230000008020 evaporation Effects 0.000 description 11
- YPSXMDISEKEGKH-UHFFFAOYSA-N n,3,5-trimethylpiperidin-4-amine Chemical compound CNC1C(C)CNCC1C YPSXMDISEKEGKH-UHFFFAOYSA-N 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 10
- XOQQVKDBGLYPGH-UHFFFAOYSA-N 2-oxo-1h-quinoline-3-carboxylic acid Chemical class C1=CC=C2NC(=O)C(C(=O)O)=CC2=C1 XOQQVKDBGLYPGH-UHFFFAOYSA-N 0.000 description 10
- 108010041052 DNA Topoisomerase IV Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 239000012458 free base Substances 0.000 description 10
- 229960003923 gatifloxacin Drugs 0.000 description 10
- 229960003376 levofloxacin Drugs 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- 206010041925 Staphylococcal infections Diseases 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- 235000011152 sodium sulphate Nutrition 0.000 description 9
- HDHZKCZZHXUICO-UHFFFAOYSA-N 3,3-dimethylpiperidin-4-amine Chemical compound CC1(C)CNCCC1N HDHZKCZZHXUICO-UHFFFAOYSA-N 0.000 description 8
- ILNJBIQQAIIMEY-UHFFFAOYSA-N 4-oxo-1h-quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CN=C21 ILNJBIQQAIIMEY-UHFFFAOYSA-N 0.000 description 8
- 239000004475 Arginine Substances 0.000 description 8
- 108010054814 DNA Gyrase Proteins 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 8
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 239000004472 Lysine Substances 0.000 description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 241000295644 Staphylococcaceae Species 0.000 description 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 8
- 229960003121 arginine Drugs 0.000 description 8
- 235000009697 arginine Nutrition 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 229950006191 gluconic acid Drugs 0.000 description 8
- 229960002885 histidine Drugs 0.000 description 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 8
- 229960003646 lysine Drugs 0.000 description 8
- 229960003808 nadifloxacin Drugs 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 8
- 229960004799 tryptophan Drugs 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
- 229960003405 ciprofloxacin Drugs 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- PZQUEAMFJFUJGG-UHFFFAOYSA-N n-cyclopropyl-3,5-dimethylpiperidin-4-amine Chemical compound CC1CNCC(C)C1NC1CC1 PZQUEAMFJFUJGG-UHFFFAOYSA-N 0.000 description 7
- 125000003386 piperidinyl group Chemical group 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- YKQMBPQMCWGNDY-UHFFFAOYSA-N 1-benzyl-3,3-dimethylpiperidin-4-one Chemical compound C1CC(=O)C(C)(C)CN1CC1=CC=CC=C1 YKQMBPQMCWGNDY-UHFFFAOYSA-N 0.000 description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 6
- 239000004473 Threonine Substances 0.000 description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 6
- 229960003767 alanine Drugs 0.000 description 6
- 235000004279 alanine Nutrition 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 229960001230 asparagine Drugs 0.000 description 6
- 235000009582 asparagine Nutrition 0.000 description 6
- 229960005261 aspartic acid Drugs 0.000 description 6
- 235000003704 aspartic acid Nutrition 0.000 description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 229960002433 cysteine Drugs 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- YFNYBCZFBHPFMW-UHFFFAOYSA-N ethyl 4-(ethylamino)-3,5-dimethylpiperidine-1-carboxylate Chemical compound CCNC1C(C)CN(C(=O)OCC)CC1C YFNYBCZFBHPFMW-UHFFFAOYSA-N 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 229960002989 glutamic acid Drugs 0.000 description 6
- 235000013922 glutamic acid Nutrition 0.000 description 6
- 239000004220 glutamic acid Substances 0.000 description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 235000004554 glutamine Nutrition 0.000 description 6
- 229960002743 glutamine Drugs 0.000 description 6
- 229960002449 glycine Drugs 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 150000002367 halogens Chemical class 0.000 description 6
- 150000003949 imides Chemical class 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229960000310 isoleucine Drugs 0.000 description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 6
- 229960003136 leucine Drugs 0.000 description 6
- 239000003120 macrolide antibiotic agent Substances 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 6
- 229960004452 methionine Drugs 0.000 description 6
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 6
- 150000007522 mineralic acids Chemical class 0.000 description 6
- JYJTVFIEFKZWCJ-UHFFFAOYSA-N nadifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)CCC3=C1N1CCC(O)CC1 JYJTVFIEFKZWCJ-UHFFFAOYSA-N 0.000 description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 6
- 229960005190 phenylalanine Drugs 0.000 description 6
- 229960002429 proline Drugs 0.000 description 6
- 229960001153 serine Drugs 0.000 description 6
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 6
- 229960004954 sparfloxacin Drugs 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 229960002898 threonine Drugs 0.000 description 6
- 229960000497 trovafloxacin Drugs 0.000 description 6
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 6
- 229960004441 tyrosine Drugs 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
- 229960004295 valine Drugs 0.000 description 6
- 239000004474 valine Substances 0.000 description 6
- ZSWUAMLORPBSTM-UHFFFAOYSA-N 1-benzyl-3,3-dimethylpiperidin-4-amine Chemical compound C1CC(N)C(C)(C)CN1CC1=CC=CC=C1 ZSWUAMLORPBSTM-UHFFFAOYSA-N 0.000 description 5
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 5
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 5
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 5
- 102100033636 Histone H3.2 Human genes 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101000871895 Homo sapiens Histone H3.2 Proteins 0.000 description 5
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical group C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000004599 antimicrobial Substances 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- CJXIYPTVYDXXDI-UHFFFAOYSA-N ethyl 3,5-dimethyl-4-oxopiperidine-1-carboxylate Chemical compound CCOC(=O)N1CC(C)C(=O)C(C)C1 CJXIYPTVYDXXDI-UHFFFAOYSA-N 0.000 description 5
- YQONNJPKBHDJJM-UHFFFAOYSA-N ethyl 3-methyl-4-oxopiperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(=O)C(C)C1 YQONNJPKBHDJJM-UHFFFAOYSA-N 0.000 description 5
- WKISUMJQVKZSBG-UHFFFAOYSA-N ethyl 4-(cyclopropylamino)-3,5-dimethylpiperidine-1-carboxylate Chemical compound CC1CN(C(=O)OCC)CC(C)C1NC1CC1 WKISUMJQVKZSBG-UHFFFAOYSA-N 0.000 description 5
- 230000002349 favourable effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- QDZDQKRSBWFIAK-UHFFFAOYSA-N n-ethyl-3,5-dimethylpiperidin-4-amine Chemical compound CCNC1C(C)CNCC1C QDZDQKRSBWFIAK-UHFFFAOYSA-N 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 229960001866 silicon dioxide Drugs 0.000 description 5
- KZTWONRVIPPDKH-UHFFFAOYSA-N 2-(piperidin-1-yl)ethanol Chemical compound OCCN1CCCCC1 KZTWONRVIPPDKH-UHFFFAOYSA-N 0.000 description 4
- CMNKORJUGMNSRJ-UHFFFAOYSA-N 3,3,5-trimethylpiperidin-4-amine Chemical compound CC1CNCC(C)(C)C1N CMNKORJUGMNSRJ-UHFFFAOYSA-N 0.000 description 4
- SCEYNOTZAXPNIY-UHFFFAOYSA-N 3-ethyl-3-methylpiperidin-4-amine Chemical compound CCC1(C)CNCCC1N SCEYNOTZAXPNIY-UHFFFAOYSA-N 0.000 description 4
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 4
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 235000010419 agar Nutrition 0.000 description 4
- QGPKADBNRMWEQR-UHFFFAOYSA-N clinafloxacin Chemical compound C1C(N)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1Cl QGPKADBNRMWEQR-UHFFFAOYSA-N 0.000 description 4
- 229950001320 clinafloxacin Drugs 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- UCJSUSUPRIMWFJ-UHFFFAOYSA-N ethyl 3-ethyl-4-oxopiperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(=O)C(CC)C1 UCJSUSUPRIMWFJ-UHFFFAOYSA-N 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000001727 glucose Nutrition 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- PAIUOUOHLLEEEP-UHFFFAOYSA-N n,3-dimethylpiperidin-4-amine Chemical compound CNC1CCNCC1C PAIUOUOHLLEEEP-UHFFFAOYSA-N 0.000 description 4
- FZVOPHDUSUCYND-UHFFFAOYSA-N n,n,3-trimethylpiperidin-4-amine Chemical compound CC1CNCCC1N(C)C FZVOPHDUSUCYND-UHFFFAOYSA-N 0.000 description 4
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 4
- 229960001180 norfloxacin Drugs 0.000 description 4
- 229960001699 ofloxacin Drugs 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 125000004344 phenylpropyl group Chemical group 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000005556 structure-activity relationship Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- QVHJQCGUWFKTSE-YFKPBYRVSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical class OC(=O)[C@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-YFKPBYRVSA-N 0.000 description 3
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 3
- SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical compound C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 description 3
- XZUJMFOTXYKCTA-UHFFFAOYSA-N 1-benzyl-3-ethyl-3-methylpiperidin-4-amine Chemical compound C1CC(N)C(CC)(C)CN1CC1=CC=CC=C1 XZUJMFOTXYKCTA-UHFFFAOYSA-N 0.000 description 3
- RAWKFELASWZAQY-UHFFFAOYSA-N 1-benzyl-3-ethyl-3-methylpiperidin-4-one Chemical compound C1CC(=O)C(CC)(C)CN1CC1=CC=CC=C1 RAWKFELASWZAQY-UHFFFAOYSA-N 0.000 description 3
- KXBPUMSPCLLXRZ-UHFFFAOYSA-N 3,3-dimethylpiperidin-4-one Chemical compound CC1(C)CNCCC1=O KXBPUMSPCLLXRZ-UHFFFAOYSA-N 0.000 description 3
- NOTIVFRUVAGKJJ-UHFFFAOYSA-N 3-ethyl-n,3-dimethylpiperidin-4-amine Chemical compound CCC1(C)CNCCC1NC NOTIVFRUVAGKJJ-UHFFFAOYSA-N 0.000 description 3
- ZOHCCEOISYCJEH-UHFFFAOYSA-N 3-ethyl-n,n,3-trimethylpiperidin-4-amine Chemical compound CCC1(C)CNCCC1N(C)C ZOHCCEOISYCJEH-UHFFFAOYSA-N 0.000 description 3
- OBSJQTCTSCRURB-UHFFFAOYSA-N 7-(4-amino-3,3-dimethylpiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid;hydrochloride Chemical compound Cl.FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCC(N)C(C)(C)C1 OBSJQTCTSCRURB-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- MGQLHRYJBWGORO-LLVKDONJSA-N Balofloxacin Chemical compound C1[C@H](NC)CCCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC MGQLHRYJBWGORO-LLVKDONJSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 208000032163 Emerging Communicable disease Diseases 0.000 description 3
- AIJTTZAVMXIJGM-UHFFFAOYSA-N Grepafloxacin Chemical compound C1CNC(C)CN1C(C(=C1C)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 AIJTTZAVMXIJGM-UHFFFAOYSA-N 0.000 description 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 206010062255 Soft tissue infection Diseases 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 3
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 229950000805 balofloxacin Drugs 0.000 description 3
- MGGWXOOXFIXMCF-UHFFFAOYSA-N benzyl 4-amino-3,3-dimethylpiperidine-1-carboxylate Chemical compound C1CC(N)C(C)(C)CN1C(=O)OCC1=CC=CC=C1 MGGWXOOXFIXMCF-UHFFFAOYSA-N 0.000 description 3
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 3
- YWGPBLOOAKHZQF-UHFFFAOYSA-N benzyl n-(3,3-dimethylpiperidin-4-yl)carbamate Chemical compound CC1(C)CNCCC1NC(=O)OCC1=CC=CC=C1 YWGPBLOOAKHZQF-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 235000001046 cacaotero Nutrition 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 description 3
- CHNMCHUAWWDZHH-UHFFFAOYSA-N ethyl 3,5-dimethyl-4-(methylamino)piperidine-1-carboxylate Chemical compound CCOC(=O)N1CC(C)C(NC)C(C)C1 CHNMCHUAWWDZHH-UHFFFAOYSA-N 0.000 description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 229940050410 gluconate Drugs 0.000 description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 3
- 229960000642 grepafloxacin Drugs 0.000 description 3
- 150000002431 hydrogen Chemical group 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229960003085 meticillin Drugs 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N monoethanolamine hydrochloride Natural products NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- LTVSDBIRNKOKKA-UHFFFAOYSA-N n,n,3,3-tetramethylpiperidin-4-amine Chemical compound CN(C)C1CCNCC1(C)C LTVSDBIRNKOKKA-UHFFFAOYSA-N 0.000 description 3
- JCIHJQGIECMFCJ-UHFFFAOYSA-N n,n,3,5-tetramethylpiperidin-4-amine Chemical compound CC1CNCC(C)C1N(C)C JCIHJQGIECMFCJ-UHFFFAOYSA-N 0.000 description 3
- WQXHWNIFQVJVSZ-UHFFFAOYSA-N n-ethyl-3,3-dimethylpiperidin-4-amine Chemical compound CCNC1CCNCC1(C)C WQXHWNIFQVJVSZ-UHFFFAOYSA-N 0.000 description 3
- AXIBJJFOGYUHHJ-UHFFFAOYSA-N n-ethyl-3-methylpiperidin-4-amine Chemical compound CCNC1CCNCC1C AXIBJJFOGYUHHJ-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 3
- 231100000760 phototoxic Toxicity 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- BCSXUVZTKVXBSD-PHDIDXHHSA-N (3r,4r)-3-methylpiperidin-4-amine Chemical compound C[C@@H]1CNCC[C@H]1N BCSXUVZTKVXBSD-PHDIDXHHSA-N 0.000 description 2
- OAQDXXYGSGJMGR-RITPCOANSA-N (3r,4s)-3-methylpiperidin-4-ol Chemical compound C[C@@H]1CNCC[C@@H]1O OAQDXXYGSGJMGR-RITPCOANSA-N 0.000 description 2
- OAQDXXYGSGJMGR-WDSKDSINSA-N (3s,4s)-3-methylpiperidin-4-ol Chemical compound C[C@H]1CNCC[C@@H]1O OAQDXXYGSGJMGR-WDSKDSINSA-N 0.000 description 2
- QKDHBVNJCZBTMR-LLVKDONJSA-N (R)-temafloxacin Chemical compound C1CN[C@H](C)CN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F QKDHBVNJCZBTMR-LLVKDONJSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- HERVTRCHMAOCNM-UHFFFAOYSA-N 1-benzyl-3,3-diethylpiperidin-4-amine Chemical compound C1CC(N)C(CC)(CC)CN1CC1=CC=CC=C1 HERVTRCHMAOCNM-UHFFFAOYSA-N 0.000 description 2
- GYHFWENUVFMIBE-UHFFFAOYSA-N 1-benzyl-3,5-diethyl-3-methylpiperidin-4-amine Chemical compound C1C(C)(CC)C(N)C(CC)CN1CC1=CC=CC=C1 GYHFWENUVFMIBE-UHFFFAOYSA-N 0.000 description 2
- TYLFZMBNLFRBNH-UHFFFAOYSA-N 1-benzyl-3,5-diethylpiperidin-4-amine Chemical compound C1C(CC)C(N)C(CC)CN1CC1=CC=CC=C1 TYLFZMBNLFRBNH-UHFFFAOYSA-N 0.000 description 2
- HYERCZPARKEXQI-UHFFFAOYSA-N 1-benzyl-3-ethyl-3,5-dimethylpiperidin-4-amine Chemical compound C1C(C)C(N)C(CC)(C)CN1CC1=CC=CC=C1 HYERCZPARKEXQI-UHFFFAOYSA-N 0.000 description 2
- BXENYJFWTOWMLO-UHFFFAOYSA-N 1-benzyl-3-ethyl-n,3-dimethylpiperidin-4-amine Chemical compound C1CC(NC)C(CC)(C)CN1CC1=CC=CC=C1 BXENYJFWTOWMLO-UHFFFAOYSA-N 0.000 description 2
- OREVADLGSYLGCD-UHFFFAOYSA-N 1-benzyl-3-ethyl-n,n,3-trimethylpiperidin-4-amine Chemical compound C1CC(N(C)C)C(CC)(C)CN1CC1=CC=CC=C1 OREVADLGSYLGCD-UHFFFAOYSA-N 0.000 description 2
- OVQAJYCAXPHYNV-UHFFFAOYSA-N 1-benzyl-3-methylpiperidin-4-one Chemical compound C1CC(=O)C(C)CN1CC1=CC=CC=C1 OVQAJYCAXPHYNV-UHFFFAOYSA-N 0.000 description 2
- CTHAKBRIQNCWOJ-UHFFFAOYSA-N 1-benzyl-n,3,3-trimethylpiperidin-4-amine Chemical compound C1C(C)(C)C(NC)CCN1CC1=CC=CC=C1 CTHAKBRIQNCWOJ-UHFFFAOYSA-N 0.000 description 2
- JCSYAXRFKNHZDK-UHFFFAOYSA-N 1-benzyl-n,n,3,5-tetramethylpiperidin-4-amine Chemical compound C1C(C)C(N(C)C)C(C)CN1CC1=CC=CC=C1 JCSYAXRFKNHZDK-UHFFFAOYSA-N 0.000 description 2
- PVPHQMDNKBJGQO-UHFFFAOYSA-N 1-benzyl-n-cyclopropyl-3,3-dimethylpiperidin-4-amine Chemical compound C1CC(NC2CC2)C(C)(C)CN1CC1=CC=CC=C1 PVPHQMDNKBJGQO-UHFFFAOYSA-N 0.000 description 2
- BOZBHPFGGMLULS-UHFFFAOYSA-N 1-benzyl-n-cyclopropyl-3-ethyl-3-methylpiperidin-4-amine Chemical compound C1CC(NC2CC2)C(CC)(C)CN1CC1=CC=CC=C1 BOZBHPFGGMLULS-UHFFFAOYSA-N 0.000 description 2
- JUDDNZANMZIMBE-UHFFFAOYSA-N 1-benzyl-n-ethyl-3,3-dimethylpiperidin-4-amine Chemical compound C1C(C)(C)C(NCC)CCN1CC1=CC=CC=C1 JUDDNZANMZIMBE-UHFFFAOYSA-N 0.000 description 2
- WQJZXSSAMGZVTM-UHFFFAOYSA-N 1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound COC1=C(F)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 WQJZXSSAMGZVTM-UHFFFAOYSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- NJNYBVVRUJTWSO-UHFFFAOYSA-N 3,3,5-trimethylpiperidin-4-one Chemical compound CC1CNCC(C)(C)C1=O NJNYBVVRUJTWSO-UHFFFAOYSA-N 0.000 description 2
- JPIIHMKDXDQRGO-UHFFFAOYSA-N 3,3-diethylpiperidin-4-amine Chemical compound CCC1(CC)CNCCC1N JPIIHMKDXDQRGO-UHFFFAOYSA-N 0.000 description 2
- TZOYXRMEFDYWDQ-UHFFFAOYSA-N 3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2NC(=O)CCC2=C1 TZOYXRMEFDYWDQ-UHFFFAOYSA-N 0.000 description 2
- DJYSFNRQHHNIRQ-UHFFFAOYSA-N 3-ethylpiperidin-4-amine Chemical compound CCC1CNCCC1N DJYSFNRQHHNIRQ-UHFFFAOYSA-N 0.000 description 2
- IECMOFZIMWVOAS-UHFFFAOYSA-N 4,4-dimethylpiperidine Chemical compound CC1(C)CCNCC1 IECMOFZIMWVOAS-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- MPORYQCGWFQFLA-ONPDANIMSA-N 7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid;trihydrate Chemical compound O.O.O.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 MPORYQCGWFQFLA-ONPDANIMSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010048610 Cardiotoxicity Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 239000001358 L(+)-tartaric acid Substances 0.000 description 2
- 235000011002 L(+)-tartaric acid Nutrition 0.000 description 2
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 2
- XAGMUUZPGZWTRP-ZETCQYMHSA-N LSM-5745 Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1C1(N)CC1 XAGMUUZPGZWTRP-ZETCQYMHSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 241001466453 Laminaria Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 206010062207 Mycobacterial infection Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 208000035109 Pneumococcal Infections Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241001134658 Streptococcus mitis Species 0.000 description 2
- 241001312524 Streptococcus viridans Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 101710183280 Topoisomerase Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 231100000259 cardiotoxicity Toxicity 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical class C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229950005627 embonate Drugs 0.000 description 2
- 206010014665 endocarditis Diseases 0.000 description 2
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 2
- 229960002549 enoxacin Drugs 0.000 description 2
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 2
- FHWVQKMCUWPKKK-UHFFFAOYSA-N ethyl 1-benzyl-3-methyl-4-oxopiperidine-3-carboxylate Chemical compound C1CC(=O)C(C(=O)OCC)(C)CN1CC1=CC=CC=C1 FHWVQKMCUWPKKK-UHFFFAOYSA-N 0.000 description 2
- YPFMNHZRNXPYBG-UHFFFAOYSA-N ethyl 1-benzyl-4-oxopiperidin-1-ium-3-carboxylate;chloride Chemical compound Cl.C1CC(=O)C(C(=O)OCC)CN1CC1=CC=CC=C1 YPFMNHZRNXPYBG-UHFFFAOYSA-N 0.000 description 2
- TWPAXFMAYRBCMB-UHFFFAOYSA-N ethyl 3-ethyl-4-(methylamino)piperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(NC)C(CC)C1 TWPAXFMAYRBCMB-UHFFFAOYSA-N 0.000 description 2
- RNIIPWBACXCZNA-UHFFFAOYSA-N ethyl 3-methyl-4-(methylamino)piperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(NC)C(C)C1 RNIIPWBACXCZNA-UHFFFAOYSA-N 0.000 description 2
- GHIBVEIXQQNDCT-UHFFFAOYSA-N ethyl 4-(cyclopropylamino)-3-ethylpiperidine-1-carboxylate Chemical compound CCC1CN(C(=O)OCC)CCC1NC1CC1 GHIBVEIXQQNDCT-UHFFFAOYSA-N 0.000 description 2
- ZVUOQTOUYBSARS-UHFFFAOYSA-N ethyl 4-(dimethylamino)-3-methylpiperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(N(C)C)C(C)C1 ZVUOQTOUYBSARS-UHFFFAOYSA-N 0.000 description 2
- JYLLDHXJGYVTOA-UHFFFAOYSA-N ethyl 4-amino-3-ethylpiperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(N)C(CC)C1 JYLLDHXJGYVTOA-UHFFFAOYSA-N 0.000 description 2
- XBJBPGROQZJDOJ-UHFFFAOYSA-N fleroxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F XBJBPGROQZJDOJ-UHFFFAOYSA-N 0.000 description 2
- 229960003306 fleroxacin Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 2
- 229960002422 lomefloxacin Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229940041033 macrolides Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 2
- TWXWNGCNYWNMJR-UHFFFAOYSA-N n-(1-benzyl-3,3-dimethylpiperidin-4-yl)acetamide Chemical compound C1C(C)(C)C(NC(=O)C)CCN1CC1=CC=CC=C1 TWXWNGCNYWNMJR-UHFFFAOYSA-N 0.000 description 2
- SHMGVQVSZPVFOT-UHFFFAOYSA-N n-(5-cyclohexyl-2-methoxyphenyl)-4-methyl-3-(3-quinolin-4-ylpyridin-2-yl)oxybenzamide Chemical compound C1=C(NC(=O)C=2C=C(OC=3C(=CC=CN=3)C=3C4=CC=CC=C4N=CC=3)C(C)=CC=2)C(OC)=CC=C1C1CCCCC1 SHMGVQVSZPVFOT-UHFFFAOYSA-N 0.000 description 2
- SMIRTKHVMVGXDQ-UHFFFAOYSA-N n-cyclopropyl-3-ethyl-3-methylpiperidin-4-amine Chemical compound CCC1(C)CNCCC1NC1CC1 SMIRTKHVMVGXDQ-UHFFFAOYSA-N 0.000 description 2
- CAZWZOFUXCIGSR-UHFFFAOYSA-N n-cyclopropyl-3-methylpiperidin-4-amine Chemical compound CC1CNCCC1NC1CC1 CAZWZOFUXCIGSR-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 101150012629 parE gene Proteins 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229960002625 pazufloxacin Drugs 0.000 description 2
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 description 2
- 229960004236 pefloxacin Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- DJXNJVFEFSWHLY-UHFFFAOYSA-N quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229960003177 sitafloxacin Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 229960004576 temafloxacin Drugs 0.000 description 2
- LHSNRJGZDUFKQT-RKDXNWHRSA-N tert-butyl n-[(3r,4r)-3-methylpiperidin-4-yl]carbamate Chemical compound C[C@@H]1CNCC[C@H]1NC(=O)OC(C)(C)C LHSNRJGZDUFKQT-RKDXNWHRSA-N 0.000 description 2
- LHSNRJGZDUFKQT-BDAKNGLRSA-N tert-butyl n-[(3r,4s)-3-methylpiperidin-4-yl]carbamate Chemical compound C[C@@H]1CNCC[C@@H]1NC(=O)OC(C)(C)C LHSNRJGZDUFKQT-BDAKNGLRSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000006208 topical dosage form Substances 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- BIIBYWQGRFWQKM-JVVROLKMSA-N (2S)-N-[4-(cyclopropylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-2-[[(E)-3-(2,4-dichlorophenyl)prop-2-enoyl]amino]-4,4-dimethylpentanamide Chemical compound CC(C)(C)C[C@@H](C(NC(C[C@H](CCN1)C1=O)C(C(NC1CC1)=O)=O)=O)NC(/C=C/C(C=CC(Cl)=C1)=C1Cl)=O BIIBYWQGRFWQKM-JVVROLKMSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
- MWKYMZXCGYXLPL-ZDUSSCGKSA-N 1-[(3s)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one Chemical compound C1N(C(=O)CC)CC[C@@H]1NC1=NC=NC2=C1CN(C=1C=C(C(OC)=NC=1)C(F)(F)F)CC2 MWKYMZXCGYXLPL-ZDUSSCGKSA-N 0.000 description 1
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 description 1
- KKGVFKZJZYBUIJ-UHFFFAOYSA-N 1-benzyl-3,3,5-trimethylpiperidin-4-one Chemical compound C1C(C)(C)C(=O)C(C)CN1CC1=CC=CC=C1 KKGVFKZJZYBUIJ-UHFFFAOYSA-N 0.000 description 1
- VLZRVORNOJAIMC-UHFFFAOYSA-N 1-benzyl-3,3-diethylpiperidin-4-one Chemical compound C1CC(=O)C(CC)(CC)CN1CC1=CC=CC=C1 VLZRVORNOJAIMC-UHFFFAOYSA-N 0.000 description 1
- LDCHVRXHOCNKGN-UHFFFAOYSA-N 1-benzyl-3,3-dimethylpiperidin-4-one;n-cyclopropyl-3,3-dimethylpiperidin-4-amine Chemical compound CC1(C)CNCCC1NC1CC1.C1CC(=O)C(C)(C)CN1CC1=CC=CC=C1 LDCHVRXHOCNKGN-UHFFFAOYSA-N 0.000 description 1
- PHHINRSKGNBFRS-UHFFFAOYSA-N 1-benzyl-3,5-diethyl-3-methylpiperidin-4-one Chemical compound C1C(C)(CC)C(=O)C(CC)CN1CC1=CC=CC=C1 PHHINRSKGNBFRS-UHFFFAOYSA-N 0.000 description 1
- WSXGIMFEHBFHAY-UHFFFAOYSA-N 1-benzyl-3,5-diethylpiperidin-4-one Chemical compound C1C(CC)C(=O)C(CC)CN1CC1=CC=CC=C1 WSXGIMFEHBFHAY-UHFFFAOYSA-N 0.000 description 1
- KUUYMZATYJQLLZ-UHFFFAOYSA-N 1-benzyl-3,5-dimethylpiperidin-4-one Chemical compound C1C(C)C(=O)C(C)CN1CC1=CC=CC=C1 KUUYMZATYJQLLZ-UHFFFAOYSA-N 0.000 description 1
- ABXMLKYHDJGARN-UHFFFAOYSA-N 1-benzyl-3-ethyl-3,5-dimethylpiperidin-4-one Chemical compound C1C(C)C(=O)C(CC)(C)CN1CC1=CC=CC=C1 ABXMLKYHDJGARN-UHFFFAOYSA-N 0.000 description 1
- JUSKDLRMHAPHCU-UHFFFAOYSA-N 1-benzyl-3-ethylpiperidin-4-one Chemical compound C1CC(=O)C(CC)CN1CC1=CC=CC=C1 JUSKDLRMHAPHCU-UHFFFAOYSA-N 0.000 description 1
- MGTFEKWKCLDVNN-UHFFFAOYSA-N 1-benzyl-3-methylpiperidin-4-amine Chemical compound C1CC(N)C(C)CN1CC1=CC=CC=C1 MGTFEKWKCLDVNN-UHFFFAOYSA-N 0.000 description 1
- VUEWBPBFUKIDKK-UHFFFAOYSA-N 1-benzyl-3-methylpiperidine Chemical compound C1C(C)CCCN1CC1=CC=CC=C1 VUEWBPBFUKIDKK-UHFFFAOYSA-N 0.000 description 1
- CSHHQGIIJPWISR-UHFFFAOYSA-N 1-benzyl-n,n,3,3-tetramethylpiperidin-4-amine Chemical compound C1C(C)(C)C(N(C)C)CCN1CC1=CC=CC=C1 CSHHQGIIJPWISR-UHFFFAOYSA-N 0.000 description 1
- SJZKULRDWHPHGG-UHFFFAOYSA-N 1-benzylpiperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=CC=C1 SJZKULRDWHPHGG-UHFFFAOYSA-N 0.000 description 1
- WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical compound [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 description 1
- YSPBEFPTFBRJBH-UHFFFAOYSA-N 1-ethyl-3-methylpiperidine Chemical compound CCN1CCCC(C)C1 YSPBEFPTFBRJBH-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- ZFRUGZMCGCYBRC-UHFFFAOYSA-N 1h-1,8-naphthyridin-2-one Chemical compound C1=CC=NC2=NC(O)=CC=C21 ZFRUGZMCGCYBRC-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- RHVCCFKUACIGSM-UHFFFAOYSA-N 2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizine Chemical class C1CC2=CC=CC=C2C2N1CCCC2 RHVCCFKUACIGSM-UHFFFAOYSA-N 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- SSORSZACHCNXSJ-UHFFFAOYSA-N 2-[2-(3,4-dichlorophenyl)-3-[2-(2-hydroxypropylamino)pyrimidin-4-yl]imidazol-4-yl]acetonitrile Chemical compound ClC=1C=C(C=CC=1Cl)C=1N(C(=CN=1)CC#N)C1=NC(=NC=C1)NCC(C)O SSORSZACHCNXSJ-UHFFFAOYSA-N 0.000 description 1
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 description 1
- DILISPNYIVRDBP-UHFFFAOYSA-N 2-[3-[2-(2-hydroxypropylamino)pyrimidin-4-yl]-2-naphthalen-2-ylimidazol-4-yl]acetonitrile Chemical compound OC(CNC1=NC=CC(=N1)N1C(=NC=C1CC#N)C1=CC2=CC=CC=C2C=C1)C DILISPNYIVRDBP-UHFFFAOYSA-N 0.000 description 1
- DWKNOLCXIFYNFV-HSZRJFAPSA-N 2-[[(2r)-1-[1-[(4-chloro-3-methylphenyl)methyl]piperidin-4-yl]-5-oxopyrrolidine-2-carbonyl]amino]-n,n,6-trimethylpyridine-4-carboxamide Chemical compound CN(C)C(=O)C1=CC(C)=NC(NC(=O)[C@@H]2N(C(=O)CC2)C2CCN(CC=3C=C(C)C(Cl)=CC=3)CC2)=C1 DWKNOLCXIFYNFV-HSZRJFAPSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- RFONJRMUUALMBA-UHFFFAOYSA-N 2-methanidylpropane Chemical compound CC(C)[CH2-] RFONJRMUUALMBA-UHFFFAOYSA-N 0.000 description 1
- KTOQRRDVVIDEAA-UHFFFAOYSA-N 2-methylpropane Chemical compound [CH2]C(C)C KTOQRRDVVIDEAA-UHFFFAOYSA-N 0.000 description 1
- QDEJGQKJMKXYLM-UHFFFAOYSA-N 2h-pyrido[2,3-h][1,2]benzoxazine Chemical class C1=CC2=NC=CC=C2C2=C1C=CNO2 QDEJGQKJMKXYLM-UHFFFAOYSA-N 0.000 description 1
- IGBZQNCZFLXHIZ-UHFFFAOYSA-N 3,3-dimethylpiperidin-1-amine Chemical compound CC1(C)CCCN(N)C1 IGBZQNCZFLXHIZ-UHFFFAOYSA-N 0.000 description 1
- BLYBATJMKNZTLN-UHFFFAOYSA-N 3,5-diethyl-3-methylpiperidin-4-amine Chemical compound CCC1CNCC(C)(CC)C1N BLYBATJMKNZTLN-UHFFFAOYSA-N 0.000 description 1
- LWLLCCNPSZZONV-UHFFFAOYSA-N 3,5-diethylpiperidin-4-amine Chemical compound CCC1CNCC(CC)C1N LWLLCCNPSZZONV-UHFFFAOYSA-N 0.000 description 1
- YECOFTHXCMGRPR-UHFFFAOYSA-N 3-ethyl-3,5-dimethylpiperidin-4-amine Chemical compound CCC1(C)CNCC(C)C1N YECOFTHXCMGRPR-UHFFFAOYSA-N 0.000 description 1
- NMAQNNVQRBLRNH-UHFFFAOYSA-N 3-ethyl-n,n-dimethylpiperidin-4-amine Chemical compound CCC1CNCCC1N(C)C NMAQNNVQRBLRNH-UHFFFAOYSA-N 0.000 description 1
- JSYULFBQUYEKLN-UHFFFAOYSA-N 3-ethyl-n-methylpiperidin-4-amine Chemical compound CCC1CNCCC1NC JSYULFBQUYEKLN-UHFFFAOYSA-N 0.000 description 1
- GSWWCKZTFBFYHA-UHFFFAOYSA-N 3-methylpiperidin-1-amine Chemical compound CC1CCCN(N)C1 GSWWCKZTFBFYHA-UHFFFAOYSA-N 0.000 description 1
- BMBKNJNDLUPFSJ-UHFFFAOYSA-N 3-pyrrolidin-1-yl-1h-quinolin-2-one Chemical class O=C1NC2=CC=CC=C2C=C1N1CCCC1 BMBKNJNDLUPFSJ-UHFFFAOYSA-N 0.000 description 1
- VNTCGXMLDSKOKN-OAHLLOKOSA-N 4-[4-[[(3r)-3-methyl-4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]methyl]-1h-pyrazol-5-yl]benzonitrile Chemical compound C([C@H](N(CC1)C=2N=CC(=CC=2)C(F)(F)F)C)N1CC=1C=NNC=1C1=CC=C(C#N)C=C1 VNTCGXMLDSKOKN-OAHLLOKOSA-N 0.000 description 1
- PLGJCXZZBPACQW-UHFFFAOYSA-N 4-cyclopropyl-3,3-dimethylpiperidin-1-amine Chemical compound CC1(C)CN(N)CCC1C1CC1 PLGJCXZZBPACQW-UHFFFAOYSA-N 0.000 description 1
- RDQLEEYWPMGHLN-UHFFFAOYSA-N 4-cyclopropyl-3-methylpiperidin-1-amine Chemical compound CC1CN(N)CCC1C1CC1 RDQLEEYWPMGHLN-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- CVPCTGBYMZBRGT-UHFFFAOYSA-N 5-amino-1-cyclopropyl-7-[3-ethyl-3-methyl-4-(methylamino)piperidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical compound C1CC(NC)C(CC)(C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC CVPCTGBYMZBRGT-UHFFFAOYSA-N 0.000 description 1
- LEILBPMISZFZQK-GFCCVEGCSA-N 5-amino-7-[(7s)-7-azaniumyl-5-azaspiro[2.4]heptan-5-yl]-1-cyclopropyl-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylate Chemical compound C12([C@H](N)CN(C1)C1=C(C3=C(C(C(C(O)=O)=CN3C3CC3)=O)C(N)=C1F)C)CC2 LEILBPMISZFZQK-GFCCVEGCSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- ONPGOSVDVDPBCY-CQSZACIVSA-N 6-amino-5-[(1r)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-n-[4-(4-methylpiperazine-1-carbonyl)phenyl]pyridazine-3-carboxamide Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NN=1)N)=CC=1C(=O)NC(C=C1)=CC=C1C(=O)N1CCN(C)CC1 ONPGOSVDVDPBCY-CQSZACIVSA-N 0.000 description 1
- WUWFMDMBOJLQIV-UHFFFAOYSA-N 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid Chemical compound C1C(N)CCN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F WUWFMDMBOJLQIV-UHFFFAOYSA-N 0.000 description 1
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 1
- XTJZKALDRPVFSN-HNNXBMFYSA-N 8-n-[(2s)-3,3-dimethylbutan-2-yl]-2-n-[2-methoxy-4-(1-methylpyrazol-4-yl)phenyl]pyrido[3,4-d]pyrimidine-2,8-diamine Chemical compound C=1C=C(NC=2N=C3C(N[C@@H](C)C(C)(C)C)=NC=CC3=CN=2)C(OC)=CC=1C=1C=NN(C)C=1 XTJZKALDRPVFSN-HNNXBMFYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- MKTVKJCJFKGPHO-UHFFFAOYSA-N C(C)(=O)OC(C)=O.C(C)(=O)NC1C(CNCC1)(C)C Chemical compound C(C)(=O)OC(C)=O.C(C)(=O)NC1C(CNCC1)(C)C MKTVKJCJFKGPHO-UHFFFAOYSA-N 0.000 description 1
- HIWHHHQBFZLMEN-UHFFFAOYSA-N CS(=O)(=O)O.O=C1C(C=NC2=CC=CC=C12)C(=O)O Chemical compound CS(=O)(=O)O.O=C1C(C=NC2=CC=CC=C12)C(=O)O HIWHHHQBFZLMEN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010061765 Chromosomal mutation Diseases 0.000 description 1
- XLQCPLVFUHBACI-UHFFFAOYSA-N Cl.C(C)N.C(C)NC1C(CNCC1)C Chemical compound Cl.C(C)N.C(C)NC1C(CNCC1)C XLQCPLVFUHBACI-UHFFFAOYSA-N 0.000 description 1
- BVTRRQIORXPTGN-UHFFFAOYSA-N ClC(=O)OCC.C(=O)(OCC)NC1C(CNCC1)(C)C Chemical compound ClC(=O)OCC.C(=O)(OCC)NC1C(CNCC1)(C)C BVTRRQIORXPTGN-UHFFFAOYSA-N 0.000 description 1
- 208000037041 Community-Acquired Infections Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101100122873 Dictyostelium discoideum grlB gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- OZJOYWQNBVOSCV-UHFFFAOYSA-N FBF.COc1c(F)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1 Chemical compound FBF.COc1c(F)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1 OZJOYWQNBVOSCV-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- KHGIBXRHEFBWBB-UHFFFAOYSA-N N,N,3,5-tetramethylpiperidin-1-amine Chemical compound CN(C)N1CC(CC(C1)C)C KHGIBXRHEFBWBB-UHFFFAOYSA-N 0.000 description 1
- CRCICWMXDRMCIL-UHFFFAOYSA-N N-cyclopropyl-3-methylpiperidin-1-amine Chemical compound C1(CC1)NN1CC(CCC1)C CRCICWMXDRMCIL-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- NJCJBUHJQLFDSW-UHFFFAOYSA-N Rufloxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 NJCJBUHJQLFDSW-UHFFFAOYSA-N 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194025 Streptococcus oralis Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 208000018452 Torsade de pointes Diseases 0.000 description 1
- 208000002363 Torsades de Pointes Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- ONXFNBOZJKXCNC-ZJSXRUAMSA-N [(3aR,9bR)-9b-(4-fluorophenyl)sulfonyl-7-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-2,3a,4,5-tetrahydro-1H-benzo[e]indol-3-yl]-(4-hydroxy-1,1-dioxothian-4-yl)methanone Chemical compound OC1(CCS(=O)(=O)CC1)C(=O)N1CC[C@@]2([C@H]1CCc1cc(ccc21)C(F)(C(F)(F)F)C(F)(F)F)S(=O)(=O)c1ccc(F)cc1 ONXFNBOZJKXCNC-ZJSXRUAMSA-N 0.000 description 1
- ODUIXUGXPFKQLG-QWRGUYRKSA-N [2-(4-chloro-2-fluoroanilino)-5-methyl-1,3-thiazol-4-yl]-[(2s,3s)-2,3-dimethylpiperidin-1-yl]methanone Chemical compound C[C@H]1[C@@H](C)CCCN1C(=O)C1=C(C)SC(NC=2C(=CC(Cl)=CC=2)F)=N1 ODUIXUGXPFKQLG-QWRGUYRKSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- JVFGXECLSQXABC-UHFFFAOYSA-N ac1l3obq Chemical compound O1C(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(O)C2O)C(COCC(O)C)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC2C(O)C(O)C1OC2COCC(C)O JVFGXECLSQXABC-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 208000022506 anaerobic bacteria infectious disease Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003103 anti-anaerobic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- NMJHEBIOKBJBHM-UHFFFAOYSA-N azanium;3,5-diethyl-3-methylpiperidin-4-amine;acetate Chemical compound [NH4+].CC([O-])=O.CCC1CNCC(C)(CC)C1N NMJHEBIOKBJBHM-UHFFFAOYSA-N 0.000 description 1
- FTBPUEHFRZPEOG-UHFFFAOYSA-N azanium;3-ethyl-3,5-dimethylpiperidin-4-amine;acetate Chemical compound [NH4+].CC([O-])=O.CCC1(C)CNCC(C)C1N FTBPUEHFRZPEOG-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- QHCSLEQTUOGKAJ-UHFFFAOYSA-N benzyl 3,3-dimethyl-4-oxopiperidine-1-carboxylate Chemical compound C1CC(=O)C(C)(C)CN1C(=O)OCC1=CC=CC=C1 QHCSLEQTUOGKAJ-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- XYPOZZARRUPZNK-UHFFFAOYSA-N bis[(2-methylpropan-2-yl)oxy] carbonate Chemical compound CC(C)(C)OOC(=O)OOC(C)(C)C XYPOZZARRUPZNK-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- UMOAANUNLSUMKF-UHFFFAOYSA-N butyl n-(3,3-dimethylpiperidin-1-yl)carbamate Chemical compound CCCCOC(=O)NN1CCCC(C)(C)C1 UMOAANUNLSUMKF-UHFFFAOYSA-N 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000004112 carboxyamino group Chemical group [H]OC(=O)N([H])[*] 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940088516 cipro Drugs 0.000 description 1
- 231100000010 clastogenicity Toxicity 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 1
- DKIMAICDTRGCRT-UHFFFAOYSA-N cyclopropanamine;n-cyclopropyl-3-ethylpiperidin-4-amine Chemical compound NC1CC1.CCC1CNCCC1NC1CC1 DKIMAICDTRGCRT-UHFFFAOYSA-N 0.000 description 1
- 125000006317 cyclopropyl amino group Chemical group 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 231100000050 cytotoxic potential Toxicity 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
- LBFRWJZMFMQWTF-UHFFFAOYSA-N ethyl 4-(cyclopropylamino)-3-methylpiperidine-1-carboxylate Chemical compound CC1CN(C(=O)OCC)CCC1NC1CC1 LBFRWJZMFMQWTF-UHFFFAOYSA-N 0.000 description 1
- HBWVHKLBIDCOHJ-UHFFFAOYSA-N ethyl 4-(ethylamino)-3-methylpiperidine-1-carboxylate Chemical compound CCNC1CCN(C(=O)OCC)CC1C HBWVHKLBIDCOHJ-UHFFFAOYSA-N 0.000 description 1
- LVIDFINDEFXGRY-UHFFFAOYSA-N ethyl 4-amino-3-methylpiperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(N)C(C)C1 LVIDFINDEFXGRY-UHFFFAOYSA-N 0.000 description 1
- LIIUTFVNVAJAKG-UHFFFAOYSA-N ethyl n-(1-benzyl-3,3-dimethylpiperidin-4-yl)carbamate Chemical compound C1C(C)(C)C(NC(=O)OCC)CCN1CC1=CC=CC=C1 LIIUTFVNVAJAKG-UHFFFAOYSA-N 0.000 description 1
- SKSJFDIIYVNVPZ-UHFFFAOYSA-N ethyl n-(3,3-dimethylpiperidin-4-yl)carbamate Chemical compound CCOC(=O)NC1CCNCC1(C)C SKSJFDIIYVNVPZ-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 230000000494 facilitatory effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- UTFNXJIHONFIGH-UHFFFAOYSA-N formaldehyde;n,n,3,3-tetramethylpiperidin-4-amine Chemical compound O=C.CN(C)C1CCNCC1(C)C UTFNXJIHONFIGH-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 244000000059 gram-positive pathogen Species 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 101150059798 grlA gene Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 101150097244 grxC2 gene Proteins 0.000 description 1
- 101150070420 gyrA gene Proteins 0.000 description 1
- 101150013736 gyrB gene Proteins 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 125000005059 halophenyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- AUONNNVJUCSETH-UHFFFAOYSA-N icosanoyl icosanoate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCCCCCCCCCC AUONNNVJUCSETH-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- 210000003864 metabolising cell Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- XJKMRHACSQCNQJ-UHFFFAOYSA-N n,n,3,3-tetramethylpiperidin-1-amine Chemical compound CN(C)N1CCCC(C)(C)C1 XJKMRHACSQCNQJ-UHFFFAOYSA-N 0.000 description 1
- UQGJFKSHEAMPKR-UHFFFAOYSA-N n-(3,3-dimethylpiperidin-4-yl)acetamide Chemical compound CC(=O)NC1CCNCC1(C)C UQGJFKSHEAMPKR-UHFFFAOYSA-N 0.000 description 1
- GLXSANUPYLXYBF-UHFFFAOYSA-N n-cyclopropyl-3,3-dimethylpiperidin-4-amine Chemical compound CC1(C)CNCCC1NC1CC1 GLXSANUPYLXYBF-UHFFFAOYSA-N 0.000 description 1
- OSUUPRKVGLPDBB-UHFFFAOYSA-N n-cyclopropyl-3-ethylpiperidin-4-amine Chemical compound CCC1CNCCC1NC1CC1 OSUUPRKVGLPDBB-UHFFFAOYSA-N 0.000 description 1
- LIIWIMDSZVNYHY-UHFFFAOYSA-N n-hydroxy-2-[(1-phenylcyclopropyl)amino]pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NO)=CN=C1NC1(C=2C=CC=CC=2)CC1 LIIWIMDSZVNYHY-UHFFFAOYSA-N 0.000 description 1
- LKPFBGKZCCBZDK-UHFFFAOYSA-N n-hydroxypiperidine Chemical group ON1CCCCC1 LKPFBGKZCCBZDK-UHFFFAOYSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 231100001085 no phototoxicity Toxicity 0.000 description 1
- 231100001183 nonphototoxic Toxicity 0.000 description 1
- 101150027117 norA gene Proteins 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229950010745 olamufloxacin Drugs 0.000 description 1
- DBSMLQTUDJVICQ-CJODITQLSA-N onametostat Chemical compound NC1=C2C=CN([C@@H]3C[C@H](CCC4=CC=C5C=C(Br)C(N)=NC5=C4)[C@@H](O)[C@H]3O)C2=NC=N1 DBSMLQTUDJVICQ-CJODITQLSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 206010033072 otitis externa Diseases 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 101150110811 parC gene Proteins 0.000 description 1
- 229940055076 parasympathomimetics choline ester Drugs 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 description 1
- 229960001732 pipemidic acid Drugs 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical group NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 1
- LTEKQAPRXFBRNN-UHFFFAOYSA-N piperidin-4-ylmethanamine Chemical compound NCC1CCNCC1 LTEKQAPRXFBRNN-UHFFFAOYSA-N 0.000 description 1
- RCIMBBZXSXFZBV-UHFFFAOYSA-N piromidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCCC1 RCIMBBZXSXFZBV-UHFFFAOYSA-N 0.000 description 1
- 229960004444 piromidic acid Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- WPISAQLBRYPUGG-UHFFFAOYSA-M potassium 3-ethyl-N,3-dimethylpiperidin-4-amine hydroxide Chemical compound [OH-].[K+].CNC1C(CNCC1)(C)CC WPISAQLBRYPUGG-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 229940072132 quinolone antibacterials Drugs 0.000 description 1
- 239000002824 redox indicator Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229960004062 rufloxacin Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- HOADHZHMSLXEJQ-UHFFFAOYSA-N tert-butyl N-(3,3-dimethylpiperidin-4-yl)carbamate hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)NC1CCNCC1(C)C HOADHZHMSLXEJQ-UHFFFAOYSA-N 0.000 description 1
- HAUKUCGBYWFHFC-GDBMZVCRSA-N tert-butyl n-[(3r,4r)-1-benzyl-3-methylpiperidin-4-yl]carbamate Chemical compound C1C[C@@H](NC(=O)OC(C)(C)C)[C@H](C)CN1CC1=CC=CC=C1 HAUKUCGBYWFHFC-GDBMZVCRSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 229950008187 tosufloxacin Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000000169 tricyclic heterocycle group Chemical group 0.000 description 1
- 125000004950 trifluoroalkyl group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 239000000083 urinary anti-infective agent Substances 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28629101P | 2001-04-25 | 2001-04-25 | |
| US60/286,291 | 2001-04-25 | ||
| US28710401P | 2001-04-27 | 2001-04-27 | |
| US60/287,104 | 2001-04-27 | ||
| US34116501P | 2001-12-13 | 2001-12-13 | |
| US60/341,165 | 2001-12-13 | ||
| PCT/IN2002/000111 WO2002085886A2 (en) | 2001-04-25 | 2002-04-24 | Chiral, broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2445888A1 true CA2445888A1 (en) | 2002-10-31 |
Family
ID=27403606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002445888A Abandoned CA2445888A1 (en) | 2001-04-25 | 2002-04-24 | Chiral, broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation and compositions |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6964966B2 (enExample) |
| EP (1) | EP1392677A2 (enExample) |
| JP (1) | JP4342797B2 (enExample) |
| AU (1) | AU2002302963A1 (enExample) |
| CA (1) | CA2445888A1 (enExample) |
| WO (1) | WO2002085886A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8163769B2 (en) | 2002-03-12 | 2012-04-24 | Abbott Laboratories | Antibacterial compounds |
| EP1631570A1 (en) * | 2003-03-12 | 2006-03-08 | Abbott Laboratories | Naphthyridine derivatives as antibacterial agents |
| WO2005026145A2 (en) * | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Quinolone antibacterial agents |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| GB0321509D0 (en) * | 2003-09-13 | 2003-10-15 | Astrazeneca Ab | Chemical compounds |
| SI1675852T1 (sl) * | 2003-09-22 | 2009-06-30 | Janssen Pharmaceutica Nv | 7-amino alkilidenil-heterociklični kinoloni in naftiridoni |
| EP1694667A2 (en) * | 2003-11-20 | 2006-08-30 | Wockhardt Limited | Polymorphs of 1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3, 3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid hydrochloride and mesalyte salts |
| DE102004035203A1 (de) | 2004-07-21 | 2006-02-16 | Bayer Healthcare Ag | Substituierte Chinolone |
| US7732612B2 (en) | 2004-09-09 | 2010-06-08 | Janssen Pharmaceutica, N.V. | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones |
| WO2006087543A1 (en) | 2005-02-18 | 2006-08-24 | Astrazeneca Ab | Antibacterial piperidine derivatives |
| DE102005030524A1 (de) * | 2005-06-30 | 2007-01-18 | Aicuris Gmbh & Co. Kg | Substituierte Chinolone II |
| DE102006005861A1 (de) | 2006-02-09 | 2007-08-23 | Aicuris Gmbh & Co. Kg | Substituierte Chinolone III |
| WO2008038122A2 (en) * | 2006-09-29 | 2008-04-03 | Wockhardt Research Centre | Processes for the preparation of 7-substituted 3,3-dimethyl-4-amino-piperidino-quinolone carboxylic acid derivatives |
| US7902227B2 (en) | 2007-07-27 | 2011-03-08 | Janssen Pharmaceutica Nv. | C-7 isoxazolinyl quinolone / naphthyridine derivatives useful as antibacterial agents |
| US20100331546A1 (en) * | 2008-02-27 | 2010-12-30 | Sumitomo Chemical Company, Limited | Method for optical resolution of alkyl piperidin-3-yl carbamate and intermediate therefor |
| EP2379505A4 (en) | 2008-12-05 | 2012-10-17 | Designmedix Inc | CHLOROQUINES MODIFIED BY A MONOCYCLIC GROUP OR A FUSED CYCLE GROUP |
| WO2011034971A1 (en) * | 2009-09-15 | 2011-03-24 | Designmedix, Inc. | Modified fluoroquinolone compounds and methods of using the same |
| KR20180016485A (ko) | 2015-06-09 | 2018-02-14 | 바이엘 파마 악티엔게젤샤프트 | 무스카린성 m2 수용체의 양성 알로스테릭 조정제 |
| WO2018011017A1 (de) | 2016-07-11 | 2018-01-18 | Bayer Pharma Aktiengesellschaft | 7-substituierte 1-pyridyl-naphthyridin-3-carbonsäureamide und ihre verwendung |
| JOP20190045A1 (ar) | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
| EP3296298A1 (de) | 2016-09-14 | 2018-03-21 | Bayer Pharma Aktiengesellschaft | 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3984403A (en) | 1972-06-30 | 1976-10-05 | Takeda Chemical Industries, Ltd. | Arginine and lysine salts of acid cephalosporins |
| US3985882A (en) | 1972-11-02 | 1976-10-12 | Riker Laboratories, Inc. | Substituted benzo[ij]quinolinzine-2-carboxylic acids and derivatives thereof as bactericidal agents |
| US3924042A (en) | 1973-03-26 | 1975-12-02 | Minnesota Mining & Mfg | Method for treatment of bacterial plant disease |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4051247A (en) | 1975-04-14 | 1977-09-27 | Riker Laboratories, Inc. | Method of using 7-hydroxy-benzo[ij]quinolizine-2-carboxylic acid derivatives |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4416884A (en) | 1978-04-12 | 1983-11-22 | Otsuka Pharmaceutical Co., Ltd. | Piperazinylbenzoheterocyclic compounds |
| JPS5746986A (en) | 1980-09-02 | 1982-03-17 | Dai Ichi Seiyaku Co Ltd | Pyrido(1,2,3-de)(1,4)benzoxazine derivative |
| JPS57176987A (en) | 1981-04-24 | 1982-10-30 | Otsuka Pharmaceut Co Ltd | Pyrrolo(3,2,1-ij)quinoline-5-carboxylic acid derivative |
| NO156828C (no) | 1980-11-10 | 1987-12-02 | Otsuka Pharma Co Ltd | Analogifremgangsm te for fremstilling av antibakterielt virksomme benzoheterocykliske forbindelser. |
| JPS5781486A (en) | 1980-11-10 | 1982-05-21 | Otsuka Pharmaceut Co Ltd | Benzo(ij)quinolidine-2-carboxylic acid derivative |
| US4404207A (en) | 1981-11-06 | 1983-09-13 | Riker Laboratories, Inc. | Antimicrobial 8-substituted benzo [IJ]quinolizines |
| JPS5890511A (ja) | 1981-11-25 | 1983-05-30 | Otsuka Pharmaceut Co Ltd | 抗菌剤 |
| JPS59106488A (ja) | 1982-12-10 | 1984-06-20 | Dai Ichi Seiyaku Co Ltd | ベンゾキノリジン誘導体 |
| US4777175A (en) | 1982-09-09 | 1988-10-11 | Warner-Lambert Company | Antibacterial agents |
| US4665079A (en) | 1984-02-17 | 1987-05-12 | Warner-Lambert Company | Antibacterial agents |
| US4638067A (en) | 1982-09-09 | 1987-01-20 | Warner-Lambert Co. | Antibacterial agents |
| US4443447A (en) | 1982-10-25 | 1984-04-17 | Riker Laboratories, Inc. | Phenyl-substituted tricyclic antibacterial agents |
| US4472406A (en) | 1982-11-12 | 1984-09-18 | Riker Laboratories, Inc. | Antimicrobial 6,7-dihydro-8-(imidazol-1-yl)-5-methyl-1-oxo-1H,5H-benzo [ij]quinolizine-2-carboxylic acids and derivatives |
| DE3248507A1 (de) | 1982-12-29 | 1984-07-05 | Bayer Ag, 5090 Leverkusen | Mikrobizide mittel auf chinoloncarbonsaeure basis |
| JPS59137482A (ja) | 1983-01-26 | 1984-08-07 | Otsuka Pharmaceut Co Ltd | ピロロ〔3,2,1,−ij〕キノリン−5−カルボン酸誘導体 |
| JPS59155381A (ja) | 1983-02-22 | 1984-09-04 | Kyorin Pharmaceut Co Ltd | ベンゾキノリジンカルボン酸誘導体及びその製造法 |
| US4472407A (en) | 1983-03-17 | 1984-09-18 | Riker Laboratories, Inc. | Antimicrobial 8-alkoxy-6,7-dihydro-5-methyl-9-fluoro-1-oxo-1H,5H-benzo[ij]qu |
| US4642355A (en) | 1984-02-24 | 1987-02-10 | Otsuka Pharmaceutical Factory, Inc. | Proline derivatives |
| US5097032A (en) | 1984-07-20 | 1992-03-17 | Warner-Lambert Company | Antibacterial agents - II |
| US4822801A (en) | 1984-07-20 | 1989-04-18 | Warner-Lambert Company | 4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivative as antibacterial agents |
| JPH089597B2 (ja) | 1986-01-21 | 1996-01-31 | 杏林製薬株式会社 | 選択毒性に優れた8‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法 |
| DE3705621C2 (de) * | 1986-02-25 | 1997-01-09 | Otsuka Pharma Co Ltd | Heterocyclisch substituierte Chinoloncarbonsäurederivate |
| JPS62215572A (ja) | 1986-03-17 | 1987-09-22 | Kyorin Pharmaceut Co Ltd | キノロンカルボン酸誘導体 |
| JPS63198664A (ja) * | 1986-03-31 | 1988-08-17 | Sankyo Co Ltd | キノロンカルボン酸誘導体 |
| CN1019114B (zh) | 1986-03-31 | 1992-11-18 | 三共株式会社 | 喹啉-3-羟酸衍生物的制备方法 |
| JPS63192753A (ja) | 1987-02-05 | 1988-08-10 | Otsuka Pharmaceut Co Ltd | テトラヒドロキノリン誘導体の光学分割法 |
| US5290934A (en) * | 1987-04-16 | 1994-03-01 | Otsuka Pharmaceutical Company, Limited | Benzoheterocyclic compounds |
| US5591744A (en) | 1987-04-16 | 1997-01-07 | Otsuka Pharmaceutical Company, Limited | Benzoheterocyclic compounds |
| HU200917B (en) | 1987-07-20 | 1990-09-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical compositions comprising quinoline or naphthyridinecarboxylic acid and tetracycline derivatives as active ingredient |
| US4851418A (en) | 1987-08-21 | 1989-07-25 | Warner-Lambert Company | Naphthyridine antibacterial agents containing an α-amino acid in the side chain of the 7-substituent |
| EP0342675B1 (en) | 1988-05-19 | 1995-01-25 | Chugai Seiyaku Kabushiki Kaisha | Novel quinolonecarboxylic acid derivatives |
| DE3906365A1 (de) | 1988-07-15 | 1990-01-18 | Bayer Ag | 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe |
| FI95130C (fi) * | 1988-07-20 | 1995-12-27 | Sankyo Co | Menetelmä lääkeaineena käyttökelpoisten 4-oksokinoliini-3-karboksyylihapon johdannaisten valmistamiseksi |
| JP2688711B2 (ja) | 1988-11-10 | 1997-12-10 | 大塚製薬株式会社 | ベンゾヘテロ環化合物 |
| JP2731853B2 (ja) | 1989-01-17 | 1998-03-25 | 大塚製薬株式会社 | トリ低級アルカノイルオキシホウ素の製造法 |
| JP2688712B2 (ja) | 1989-01-17 | 1997-12-10 | 大塚製薬株式会社 | ハロゲン置換キノリン誘導体の製造法 |
| US5185337A (en) | 1989-03-29 | 1993-02-09 | Otsuka Pharmaceutical Co., Ltd. | Pyrroloquinoline derivatives and pharmaceutical compositions for antimicrobial use |
| DK545889D0 (da) | 1989-04-28 | 1989-11-02 | Daiichi Seiyaku Co | Anti-human-immundefektvirus-praeparat |
| FR2675144B1 (fr) * | 1991-04-10 | 1995-06-16 | Bouchara Sa | Nouvelles quinolones difluorees - leur procede de preparation et les compositions pharmaceutiques en renfermant. |
| US5869661A (en) | 1991-07-16 | 1999-02-09 | Chugai Seiyaku Kabushiki Kaisha | Method of producing a quinolonecarboxylic acid derivative |
| EP0541086A1 (en) | 1991-11-08 | 1993-05-12 | Kaken Pharmaceutical Co., Ltd. | Antibacterial 6-fluoro-quinolones having an oxime group on the substituent in position 7 |
| NO304832B1 (no) | 1992-05-27 | 1999-02-22 | Ube Industries | Aminokinolonderivater samt middel mot HIV |
| JPH05339238A (ja) | 1992-06-10 | 1993-12-21 | Otsuka Pharmaceut Co Ltd | テトラヒドロキノリン誘導体のラセミ化方法 |
| JPH06145167A (ja) | 1992-11-06 | 1994-05-24 | Hokuriku Seiyaku Co Ltd | 8−メトキシ−5−メチルキノリン−3−カルボン酸誘導体 |
| WO1994014794A1 (fr) | 1992-12-28 | 1994-07-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Derive d'acide 8-methoxyquinolonecarboxylique |
| KR0148277B1 (ko) | 1993-01-18 | 1998-11-02 | 채영복 | 신규한 플루오르퀴놀론계 유도체 및 그의 제조방법 |
| TW301607B (enExample) | 1993-03-09 | 1997-04-01 | Takeda Pharm Industry Co Ltd | |
| WO1994020105A1 (en) | 1993-03-10 | 1994-09-15 | Otsuka Pharmaceutical Company, Limited | Interleukin-1 inhibitor |
| US6034100A (en) | 1993-03-10 | 2000-03-07 | Otsuka Pharmaceutical Co., Ltd. | Method for inhibiting cytokine secretion |
| CA2152828A1 (en) | 1993-03-16 | 1994-07-07 | Shin-Ichi Uesato | 8-methoxy-quinolonecarboxylic acid derivatives |
| DE4342186A1 (de) | 1993-12-10 | 1995-06-14 | Bayer Ag | Eintopfverfahren zur Herstellung von 3-Chinoloncarbonsäurederivaten |
| WO1996022988A1 (en) | 1995-01-24 | 1996-08-01 | Hokuriku Seiyaku Co., Ltd. | Quinolinecarboxylic acid derivatives |
| US6121285A (en) | 1995-11-22 | 2000-09-19 | Daiichi Pharmaceutical Co., Ltd. | Substituted aminocycloalkylpyrrolidine derivatives and cis-substituted aminocycloalkylpyrrolidine derivatives |
| US5753269A (en) | 1995-12-27 | 1998-05-19 | Bayer Corporation | Otic microbial combinations |
| WO1997031000A1 (en) | 1996-02-21 | 1997-08-28 | Darwin Discovery Limited | Quinolones and their therapeutic use |
| WO1997044034A1 (en) | 1996-05-20 | 1997-11-27 | Otsuka Pharmaceutical Co., Ltd. | Remedy for rosacea |
| AU3459797A (en) | 1996-07-12 | 1998-02-09 | Daiichi Pharmaceutical Co., Ltd. | Cis-substituted aminocyclopropane derivatives |
| KR20010014209A (ko) | 1997-06-24 | 2001-02-26 | 스즈키 다다시 | 시스-치환된 플루오로메틸피롤리딘 유도체 |
| EP1015445B1 (en) | 1997-09-15 | 2009-02-25 | The Procter & Gamble Company | Antimicrobial quinolones, their compositions and uses |
| DE19751948A1 (de) | 1997-11-24 | 1999-05-27 | Bayer Ag | Verfahren zur Herstellung von 8-Methoxy-Chinoloncarbonsäuren |
| WO2000018404A1 (en) | 1998-09-30 | 2000-04-06 | Alcon Laboratories, Inc. | Antibiotic compositions for treatment of the eye, ear and nose |
| US7247642B2 (en) | 1999-05-07 | 2007-07-24 | Wockhardt Limited | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment |
| US6514986B2 (en) | 2000-11-22 | 2003-02-04 | Wockhardt Limited | Chiral fluoroquinolone arginine salt forms |
| ATE378335T1 (de) | 2000-05-08 | 2007-11-15 | Wockhardt Ltd | Chirale fluorochinolizinon arginine salze |
| WO2001085728A2 (en) | 2000-05-08 | 2001-11-15 | Wockhardt Limited | Antibacterial chiral 8-(substituted piperidino)-benzo [i, j] quinolizines, processes, compositions and methods of treatment |
| AU2001280091A1 (en) | 2000-08-01 | 2002-02-13 | Wockhardt Limited | Inhibitors of cellular efflux pumps of microbes |
-
2002
- 2002-04-23 US US10/128,996 patent/US6964966B2/en not_active Expired - Fee Related
- 2002-04-24 EP EP02730678A patent/EP1392677A2/en not_active Withdrawn
- 2002-04-24 CA CA002445888A patent/CA2445888A1/en not_active Abandoned
- 2002-04-24 JP JP2002583413A patent/JP4342797B2/ja not_active Expired - Fee Related
- 2002-04-24 WO PCT/IN2002/000111 patent/WO2002085886A2/en not_active Ceased
- 2002-04-24 AU AU2002302963A patent/AU2002302963A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1392677A2 (en) | 2004-03-03 |
| WO2002085886A2 (en) | 2002-10-31 |
| US20030096812A1 (en) | 2003-05-22 |
| AU2002302963A1 (en) | 2002-11-05 |
| JP2005504729A (ja) | 2005-02-17 |
| JP4342797B2 (ja) | 2009-10-14 |
| US6964966B2 (en) | 2005-11-15 |
| WO2002085886A3 (en) | 2003-05-22 |
| AU2002302963A8 (en) | 2005-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7626032B2 (en) | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | |
| US6964966B2 (en) | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | |
| US7868021B2 (en) | Antimicrobial quinolones, their compositions and uses | |
| AU2002230891B2 (en) | Antimicrobial quinolones | |
| KR101490222B1 (ko) | 항균성 퀴놀린 유도체 | |
| EP1453824A1 (en) | New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | |
| US7019143B2 (en) | Antimicrobial quinolones, their compositions and uses | |
| CA2417799A1 (en) | Inhibitors of cellular efflux pumps of microbes | |
| US5547962A (en) | 5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative | |
| KR101307717B1 (ko) | 트리―, 테트라― 치환―3―아미노피롤리딘 유도체 | |
| WO2001085728A2 (en) | Antibacterial chiral 8-(substituted piperidino)-benzo [i, j] quinolizines, processes, compositions and methods of treatment | |
| US6509349B1 (en) | Antimicrobial 2-pyridones, their compositions and uses | |
| US6608078B2 (en) | Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment | |
| AU2002230893A1 (en) | Antimicrobial 2-pyridones, their compositions and uses | |
| IE65175B1 (en) | 7-(2-methyl-4-aminopyrrolidin-1-yl) naphthyridine and quinoline compounds | |
| CA2468190A1 (en) | New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | |
| Bhawsar et al. | WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections | |
| WO2005030752A1 (ja) | 8−シアノキノロンカルボン酸誘導体 | |
| WO2005066154A2 (en) | Polymorphs of 1-cyclopropyl-6-fuoro-8-methoxy-7-(4-amino-3, 3-dimethylpiperidin-1-yl) -1, 4-dihydro-4-oxo-quinoline-3-carboxylic acid hydrochloride and mesalyte salts | |
| HK1030415B (en) | Antimicrobial quinolones, their compositions and uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |